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A B S T R A C T
Background
People with venous thromboembolism (VTE) generally are treated for five days with intravenous unfractionated heparin or subcutaneous
low-molecular-weight heparin (LMWH), followed by three months of vitamin K antagonists (VKAs). Treatment with VKAs requires
regular laboratory measurements and carries risk of bleeding; some patients have contraindications to such treatment. Treatment with
LMWH has been proposed to minimise the risk of bleeding complications. This is the second update of a review first published in
2001.
Objectives
The purpose of this review was to evaluate the efficacy and safety of long term treatment (three months) with LMWH versus long term
treatment (three months) with VKAs for symptomatic VTE.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched November 2016) and
the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 10), The Cochrane Vascular Information Specialistalso
searched clinical trials registries for ongoing studies.
Selection criteria
Randomised controlled trials comparing LMWH versus VKA for long treatment (three months) of symptomatic VTE. Two review
authors independently evaluated trials for inclusion and methodological quality.
Data collection and analysis
Review authors independently extracted data and assessed risk of bias. We resolved disagreements by discussion and performed meta-
analysis using fixed-effect models with Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs). Outcomes of interest were
recurrent VTE, major bleeding, and mortality. We used GRADE to assess the overall quality of evidence supporting these outcomes.
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Main results
Sixteen trials, with a combined total of 3299 participants fulfilled our inclusion criteria. According to GRADE, the quality of evidence
was moderate for recurrent VTE, low for major bleeding, and moderate for mortality. We downgraded the quality of the evidence for
imprecision (recurrent VTE, mortality) and for risk of bias and inconsistency (major bleeding).
We found no clear differences in recurrent VTE between LMWH and VKA (Peto OR 0.83, 95% confidence interval (CI) 0.60 to
1.15; P = 0.27; 3299 participants; 16 studies; moderate-quality evidence). We found less bleeding with LMWH than with VKA (Peto
OR 0.51, 95% CI 0.32 to 0.80; P = 0.004; 3299 participants; 16 studies; low-quality evidence). However, when comparing only high-
quality studies for bleeding, we observed no clear differences between LMWH and VKA (Peto OR 0.62, 95% CI 0.36 to 1.07; P =
0.08; 1872 participants; seven studies). We found no clear differences between LMWH and VKA in terms of mortality (Peto OR 1.08,
95% CI 0.75 to 1.56; P = 0.68; 3299 participants; 16 studies; moderate-quality evidence).
Authors’ conclusions
Moderate-quality evidence shows no clear differences between LMWH and VKA in preventing symptomatic VTE and death after an
episode of symptomatic DVT. Low-quality evidence suggests fewer cases of major bleeding with LMWH than with VKA. However,
comparison of only high-quality studies for bleeding shows no clear differences between LMWH and VKA. LMWHmay represent an
alternative for some patients, for example, those residing in geographically inaccessible areas, those who are unable or reluctant to visit
the thrombosis service regularly, and those with contraindications to VKA.
P L A I N L A N G U A G E S U M M A R Y
Vitamin K antagonists or low-molecular-weight heparin for long term treatment of symptomatic blood clots
Background
Blood clots (venous thromboembolism) sometimes cause blockages in veins after surgery, during bed rest, or spontaneously. These clots
can be fatal when they travel to the lungs. Vitamin K antagonists (VKAs), 99% of which consist of warfarin, are effective in preventing
renewed blood clot formation, because they thin the blood. Low-molecular-weight heparins (LMWHs) are drugs that thin the blood
and are used for people who are at risk of major bleeding, people who cannot take vitamin K antagonists, and pregnant women.
Purpose of the review
To assess the benefits and harms of long term treatment (three months) of venous thromboembolism with LMWH compared with
long term treatment with VKAs.
Key results
This systematic review of 16 trials with a combined total of 3299 participants (current until November 2016) found no clear differences
in recurrent blood clots and deaths between LMWH and VKA, and fewer bleeding episodes with LMWH than with VKA. However,
comparison of only high-quality studies for bleeding revealed no clear differences between LMWH and VKA.
Quality of the evidence
The quality of evidence for the outcomes recurrent blood clots and death was moderate. The quality of this evidence was downgraded
because of the small number of events reported, leading to imprecision. For the outcome bleeding, the quality of evidence was low
because of inconsistency between studies and risk of bias. Continued research into long term treatment of blood clots in the veins with
LMWH and VKA is needed.
Authors’ conclusions
This review found no clear differences in recurrent blood clots and death between LMWH and VKA, and fewer bleeding episodes with
LMWH than with VKA. However, when only high-quality studies were compared for bleeding, no clear differences were observed
between LMWH and VKA. LMWHmay offer an alternative for some patients, for example, those in geographically inaccessible areas,
those unable or reluctant to visit the thrombosis service regularly, and those for whom taking VKA may be harmful.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LMWH compared with VKA for long term treatment of symptomatic VTE
Patient or population: pat ients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
Setting: hospital and outpat ient
Intervention: LMWH
Comparison: VKA
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with VKA Risk with LMWH
Incidence of recurrent
VTE
(t reatment durat ion 3
months)
Study populat ion Peto OR 0.83
(0.60 to 1.15)
3299
(16 RCTs)
⊕⊕⊕©
MODERATEa,b
51 per 1000 42 per 1000
(31 to 58)
Incidence of major
bleeding
(t reatment durat ion 3
months)
Study populat ion Peto OR 0.51
(0.32 to 0.80)
3299
(16 RCTs)
⊕⊕©©
LOWc,d
29 per 1000 15 per 1000
(10 to 24)
Mortality
(t reatment durat ion 3
months)
Study populat ion Peto OR 1.08
(0.75 to 1.56)
3299
(16 RCTs)
⊕⊕⊕©
MODERATEa,b
35 per 1000 37 per 1000
(26 to 53)
* The basis for the assumed risk with VKA for ’Study populat ion’ was the average risk in the VKA group (i.e. total number of part icipants with events divided by total number
of part icipants in the VKA group included in the meta-analysis). The risk in the LMWH group (and its 95% conf idence interval) is based on assumed risk in the VKA group and
the relative effect of the intervent ion (and its 95%CI)
CI: conf idence interval; LMWH: low-molecular-weight heparin; OR: odds rat io; VKA: vitamin K antagonist ; VTE: venous thromboembolism
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh risk of bias due to no blinding but not downgraded, as analysis excluding studies deemed of low methodological quality
conf irms no clear dif f erences between LMWH and VKA
bDowngraded by one level owing to imprecision, small number of events, and relat ively large conf idence interval
cDowngraded by one level for risk of bias, as sensit ivity analysis based on category I trials (clearly concealed randomisat ion,
double-blind or blinded outcome assessment) shows no clear dif f erences between VKA and LMWH. Bleeding outcomes are
more suscept ible to biased outcome report ing than outcomes such as VTE and mortality
dDowngraded by one level for inconsistency: only two studies (studies of low methodological quality) reported less bleeding
for LMWH, and the remainder showed no clear dif f erences, with conf idence intervals crossing the line of no ef fect
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B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE) is defined as formation of
thrombus in the deep veins, most commonly in the legs (deep vein
thrombosis, or DVT), and/or subsequent embolisation of all or
part of the thrombus to the pulmonary circulation (pulmonary
embolisation, or PE). DVT of the lower limbs may be associated
with localised pain, swelling, and erythema, as well as with devel-
opment of pulmonary emboli (PE) and later occurrence of post-
thrombotic syndrome (PTS; persistent swelling, erythema, and ul-
ceration). PE presents acutely with shortness of breath, pain on in-
spiration, tachycardia, and right heart overload, and, if untreated,
can lead to circulatory collapse and death; over the longer term, PE
can cause chronic post-thrombotic pulmonary hypertension. In
this era of more liberal central venous catheterisation, DVT may
more often involve the upper extremities. Rarely, other venous cir-
culation (within cerebral veins, portal and mesenteric veins, etc.)
can be affected.
In addition to DVT and PE, thrombus can form in the superfi-
cial veins, where it is associated with local pain and inflammation
(superficial venous thrombosis). This event tends to be associated
with lower rates of mortality and morbidity than are seen with
DVT, although some patients may be at higher risk of DVT for-
mation depending on the location of the clot (Chengelis 1996;
Nasr 2015).
Venous thromboembolism (VTE) comprisesDVTandPE and can
occur spontaneously. However, risk factors for VTE are many and
include periods of inactivity, dehydration, hospitalisation, trauma,
clotting disorders and previous thrombosis, varicose veins with
phlebitis, pregnancy, use of oral combined hormonal contracep-
tives, malignancy, obesity, smoking, and advanced age (Anderson
2003; NICE 2010).
The incidence of VTE inmostly Caucasian populations is between
100 and 200 per 100,000 person-years (Heit 2015; White 2003).
Of these, it is estimated that 45 to 117 per 100,000 person-years
are due to DVT (without PE) and 29 to 78 per 100,000 person-
years to PE (with or without DVT) (Heit 2015). Recurrent VTE
occurs in approximately 7.4% of patients at one year and in 30.4%
of patients by 10 years (Cushman 2007; Heit 2015; White 2003).
Description of the intervention
The primary aim of treatment of symptomatic VTE is preven-
tion of its recurrence, including prevention of potentially fatal
PE. Clinical guidelines provide recommendations for treatment of
VTE in different settings (Kearon 2016; NICE 2012). In general,
anticoagulation is the recommended treatment of choice. The rec-
ommended initial treatment consists of a direct oral anticoagulant
(with or without initial parenteral anticoagulation as indicated) or
a parenteral anticoagulant given in conjunction with a VKA. Long
term therapy (usually for a minimum duration of three months of
anticoagulation) is indicated for treatment of acute VTE.
Prolonged use of a VKA has proven efficacy in comparison with
placebo and low-dose heparin (unfractionated heparin) for treat-
ment of VTE (Hull 1979; Lagerstedt 1985). Use of adjusted thera-
peutic doses of subcutaneous unfractionated heparin is as effective
as use of a VKA for preventing recurrence of symptomatic VTE,
but both require regular laboratory monitoring (Hull 1982b).
Usual practice is to administer VKAs to achieve an international
normalised ratio (INR) of 2.0 to 3.0 (Hull 1982a). However, use
of VKAs continues to present considerable risk of major bleeding
(approximately 3% to 4%) during the first three months of treat-
ment (Hutten 1999). Moreover, for some patients, it is difficult
to achieve a stable INR in the therapeutic range, and this leads to
increased risk of bleeding complications.
How the intervention might work
Long term treatment of symptomatic VTE with low-molecular-
weight heparin (LMWH) has been proposed to minimise risk of
bleeding complications. Comparison of LMWH versus unfrac-
tionated heparin for initial treatment of symptomatic VTE re-
veals that LMWH is associated with a reduction in major bleed-
ing (Hettiarachchi 1998), and that treatment with LMWH is less
frequently complicated by thrombocytopaenia (Warkentin 1995)
and osteoporosis (Kelton 1995; Monreal 1994); also, these com-
pounds do not require laboratory monitoring.
Why it is important to do this review
If the efficacy and safety of LMWH are found to be comparable
with those of VKAs, LMWH could be used for long term treat-
ment of symptomatic VTE. This would be especially important
for patients in whom VKAs are contraindicated or impractical,
for example, pregnant women and those living in geographically
inaccessible places.
O B J E C T I V E S
The purpose of this review was to evaluate the efficacy and safety
of long term treatment (three months) with LMWH versus long
term treatment (three months) with VKAs for symptomatic VTE.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We included trials that randomly allocated participants to long
term (three months) treatment with VKAs or LMWH.
Types of participants
We included trials involving participants with symptomatic ve-
nous thromboembolism (VTE).We excluded trials that exclusively
included participants with active malignancy and symptomatic
VTE because this is the topic of another Cochrane review (Akl
2014). In addition, we excluded trials when investigators did not
use objective tests to confirm the diagnosis of deep venous throm-
bosis (DVT) (such as venography, ultrasound, or any sequence of
tests that results in a high positive predictive value for the diagnosis
of symptomatic DVT) or the diagnosis of pulmonary embolism
(PE) (such as high-probability ventilation-perfusion lung scan or
pulmonary angiography).
Types of interventions
We included trials comparing VKAs versus LMWH for long term
(three months) treatment of symptomatic VTE. Trials were in-
cluded if the initial treatment for symptomatic VTE consisted of
LMWH or unfractionated heparin for 5 to 10 days.
Types of outcome measures
Primary outcomes
• Incidence of recurrent symptomatic VTE during three
months of allocated treatment
• Occurrence of major bleeding complications during three
months of allocated treatment
• Mortality during three months of allocated treatment
To confirm an episode of suspected recurrent VTE, we considered
the following criteria as constituting a positive diagnosis of recur-
rent symptomatic DVT.
• Extension of an intraluminal filling defect on a venogram.
• New intraluminal filling defect.
• Extension of non-visualisation of proximal veins in the
presence of a sudden cut-off defect on a venogram seen on at
least two projections.
When no previous venogram was available for comparison, we
considered an intraluminal filling defect as sufficient. When no
venogram was available, we accepted abnormal results of com-
pression ultrasonography in an area where compression had previ-
ously been normal, or a substantial increase in the diameter of the
thrombus during full compression at the popliteal or femoral vein
(Koopman 1996; Levine 1996). When neither a venogram nor
an ultrasonographic trial was available, a change in the results of
impedance plethysmography from normal to abnormal, accom-
panied by a change from a negative to a positive result on a D-
dimer test, was acceptable.
To confirm an episode of suspected recurrent PE, we accepted the
following criteria.
• New intraluminal filling defect.
• Extension of an existing defect.
• Sudden cut-off of vessels > 2.5 mm in diameter on a
pulmonary angiogram.
When no prior pulmonary angiogram was available, an intralu-
minal filling defect or a sudden cut-off of vessels > 2.5 mm in
diameter on a pulmonary angiogram was sufficient.When no pul-
monary angiogram was available, we accepted a defect of ≥ 75%
of a segment on the perfusion scan with normal ventilation.When
the ventilation-perfusion scan was non-diagnostic (and no pul-
monary angiogram was available), satisfaction of the above criteria
for DVT was acceptable. Pulmonary embolism demonstrated at
autopsy was also acceptable.
We classified haemorrhages as major if they were clinically overt
and associated with a fall in haemoglobin level ≥ 2 g/dL (1.6
mM); clinically overt and leading to transfusion of ≥ 2 units
of packed cells; intracranial; retroperitoneal; leading directly to
death; or leading to interruption of antithrombotic treatment or
(re)operation.
We excluded studies that evaluated bleeding if definitions of major
and minor bleeding were unclear.
Secondary outcomes
• Incidence of recurrent symptomatic VTE during additional
six to nine months after cessation of allocated three months of
treatment for symptomatic VTE
• Occurrence of major bleeding complications during
additional six to nine months after cessation of allocated three
months of treatment for symptomatic VTE
• Mortality during additional six to nine months after
cessation of allocated three months of treatment for symptomatic
VTE
We considered additional long term outcomes for inclusion in the
review when these were available.
Search methods for identification of studies
We applied no language restrictions on publications and no re-
strictions regarding status of publications.
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
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• Cochrane Vascular Specialised Register (11 November
2016).
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 10) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINE Ovid, Embase Ovid, the Cumulative Index to Nursing and
Allied Health Literature (CINAHL), and the Allied and Comple-
mentary Medicine Database (AMED), and through handsearch-
ing of relevant journals. The full list of the databases, journals and
conference proceedings which have been searched, as well as the
search strategies used are described in the Specialised Register sec-
tion of the Cochrane Vascular module in The Cochrane Library (
www.cochranelibrary.com).
The CIS searched the following trial registries for details of ongo-
ing and unpublished studies (11 November 2016).
• ClinicalTrials.gov ( www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform ( www.who.int/trialsearch).
• ISRCTN Register ( www.isrctn.com/).
See Appendix 2.
Searching other resources
We searched the reference lists of articles retrieved by electronic
searches for additional citations. We contacted trialists for further
informationwhendataweremissing, orwhenwe haddoubts about
whether we should include specific trials in the review.
Data collection and analysis
Selection of studies
At least two members of the current review author team (AA, AST,
MS) independently scrutinised trials for eligibility and resolved
disagreements by discussion. We obtained full versions of articles
that potentially met our inclusion criteria upon review of titles
or abstracts and assessed these trials independently against the
inclusion criteria. We have presented the reason for exclusion of
each study in the Characteristics of excluded studies table.
Data extraction and management
We reviewed eligible articles and extracted and recorded sum-
mary information on forms developed by Cochrane Vascular. We
sought the following information: participant characteristics (age,
gender, comorbidities); number of participants in each treatment
arm; duration of therapy; type of anticoagulant (vitamin K an-
tagonist/LMWH); and incidence and timing of recurrent VTE,
major bleeding complications, andmortality.When important in-
formation was not reported, we contacted trial authors.
Assessment of risk of bias in included studies
Two review authors working independently (AA, MS) used the
’Risk of bias tool’ as described in theCochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011) to assess sequence gen-
eration, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting, and other sources of bias, judg-
ing each item to be at low, unclear, or high risk of bias according
to guidance provided in the Cochrane Handbook for Systematic Re-
views of Interventions.
We then classified trials into two categories. Category I trials were
those with high methodological quality, that is, clearly concealed
randomisation and double-blind treatment or blinded assessment
of outcome measures. Category II trials were those with lower
methodological quality, that is, unclear or clearly not concealed
randomisation or blind outcome assessment. We sought all infor-
mation regarding adequacy of the randomisation process, alloca-
tion concealment, blinding, intention-to-treat analysis, and com-
pleteness of follow-up.
Measures of treatment effect
We used Review Manager 5.3 as provided by Cochrane to anal-
yse data. For dichotomous outcomes, we have presented results of
statistical analysis as Peto odds ratios (Peto ORs) with 95% confi-
dence intervals (CIs).
Unit of analysis issues
Participating individuals were the unit of analysis.
Dealing with missing data
When necessary, we contacted the authors of included trials to
clarify data and provide missing values.
Assessment of heterogeneity
We conducted all analyses on an intention-to-treat basis. When
individual trials did not use intention-to-treat analysis, we analysed
data (absolute numbers) as provided in the included trial report.
We assessed trial heterogeneity using the I2 statistic, which de-
scribes the percentage of variability in effect estimates that is due
to heterogeneity rather than to sampling error (chance). When we
identified heterogeneity (I2 > 50%), we investigated reasons for
this.
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Assessment of reporting biases
We used asymmetry in funnel plots to assess reporting bias when
we included more than 10 studies in the meta-analysis (Higgins
2011).
Data synthesis
We combined calculated Peto ORs from individual trials across
trials, giving weight to the number of events reported in each of
the two treatment groups for each separate trial. This approach
assumes the use of a fixed-effect analysis model (Collins 1987;
Mantel 1959).
We performed separate analyses for all trials combined and for
trials of high methodological quality (Category I) (see Assessment
of risk of bias in included studies).
Subgroup analysis and investigation of heterogeneity
We performed separate analyses for trials that used similar ini-
tial treatment in both trial arms and for those that used different
treatment regimens during initial treatment for PE or DVT (i.e.
LMWH vs unfractionated heparin for initial treatment of symp-
tomatic VTE - a potential source of confounding). In addition, we
performed analyses for symptomatic PE and symptomatic DVT
to explore the effects of vitamin K antagonists on these two dif-
ferent disease components of symptomatic VTE.
Sensitivity analysis
The primary analysis included data on all trial participants during
the period of randomly allocated treatment. We performed sensi-
tivity analyses to explore the effect that risk of bias had on estimates
of treatment effects by excluding studies classified as category II
trials (trials with lowmethodological quality, i.e. unclear or clearly
not concealed randomisation or no blind outcome assessment; see
Assessment of risk of bias in included studies).
’Summary of findings’
We presented the main findings of this review regarding quality
of evidence, magnitude of effects of interventions examined, and
sum of available data on primary outcomes (Types of outcome
measures) in a ’Summary of findings’ table, according to GRADE
principles as described by Higgins 2011 and Atkins 2004. We de-
veloped a ’Summary of findings’ table for the comparison ’LMWH
versus VKA during allocated treatment ( category I and II stud-
ies)’ and used GRADEpro ( GRADEproGDT) software ( http:/
/www.guidelinedevelopment.org/) to facilitate preparation of the
’Summary of findings’ table.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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We identified one new study that was eligible for inclusion in this
update (Perez-de-Llano 2010).
Included studies
In total, 16 trials that examined long term treatment of symp-
tomatic VTE fulfilled our inclusion criteria (Beckman 2003;
Das 1996; Daskalopoulos 2005; Gonzalez 1999; Hamann 1998;
Hull 2007; Hull 2009; Kakkar 2003; Kucher 2005; Lopaciuk
1999; Lopez 2001; Massicotte 2003; Perez-de-Llano 2010; Pini
1994; Romera 2009; Veiga 2000). Three trials (Beckman 2003;
Kucher 2005; Perez-de-Llano 2010) included only participants
with symptomatic PE. One trial included participants with both
symptomatic DVT and symptomatic PE (Massicotte 2003). The
12 remaining trials included participants with symptomatic DVT.
See the Characteristics of included studies table for a detailed de-
scription of these trials.
The trials were performed in the following countries.
• Canada (Hull 2007; Hull 2009; Massicotte 2003).
• Germany (Hamann 1998).
• Greece (Daskalopoulos 2005).
• Italy (Pini 1994).
• Poland (Lopaciuk 1999).
• Spain (Gonzalez 1999; Lopez 2001; Perez-de-Llano 2010;
Romera 2009; Veiga 2000).
• USA (Beckman 2003; Kakkar 2003; Kucher 2005).
• UK (Das 1996).
The 16 included trials recruited a total of 3299 participants. The
number of participants in each trial ranged from40 (Kucher 2005)
to 737 (Hull 2007). Seven trials provided similar treatments in
both arms (Das 1996; Daskalopoulos 2005; Gonzalez 1999; Hull
2007; Hull 2009; Perez-de-Llano 2010; Pini 1994); the remaining
nine trials allocated participants to different treatments provided
in different trial arms (Beckman 2003; Hamann 1998; Kakkar
2003; Kucher 2005; Lopaciuk 1999; Lopez 2001; Massicotte
2003; Romera 2009; Veiga 2000). The 16 included trials were
published between 1994 and 2010 (Beckman 2003; Das 1996;
Daskalopoulos 2005; Gonzalez 1999; Hamann 1998; Hull 2007;
Hull 2009; Kakkar 2003; Kucher 2005; Lopaciuk 1999; Lopez
2001; Massicotte 2003; Perez-de-Llano 2010; Pini 1994; Romera
2009; Veiga 2000).
Category I trials were those with high methodological quality, that
is, clearly concealed randomisation and double-blind treatment
or blinded assessment of outcome measures. Category II trials
were those with lower methodological quality, that is unclear or
clearly not concealed randomisation or blind outcome assessment.
We deemed that seven trials were category I trials (Das 1996;
Daskalopoulos 2005; Gonzalez 1999; Hull 2007; Hull 2009;
Massicotte 2003; Pini 1994) and the remaining nine trials were
category II trials (Beckman 2003; Hamann 1998; Kakkar 2003;
Kucher 2005; Lopaciuk 1999; Lopez 2001; Perez-de-Llano 2010;
Romera 2009; Veiga 2000). For additional details onmethodolog-
ical quality, see the Risk of bias in included studies section.
Seven of the 16 trials included only participants with symptomatic
DVT and used similar initial treatment in both treatment arms.
These included two category I trials (Das 1996; Pini 1994) and
five category II trials (Hamann 1998; Lopaciuk 1999; Lopez 2001;
Romera 2009; Veiga 2000). The category II trial Kakkar 2003
randomised participants between three treatment arms; in one
arm, initial treatment was intravenous unfractionated heparin fol-
lowed by three months of VKA. The other two treatment arms
initially treated participants with LMWH followed by a VKA or
LMWH for 12 weeks. In the category I trials Gonzalez 1999,
Daskalopoulos 2005, and Hull 2007, initial treatment in the
LMWH arm consisted of subcutaneous LMWH, and initial treat-
ment in the VKA arm consisted of a course of intravenous un-
fractionated heparin. Category I trial Hull 2009 included only
participants with acute proximal DVT; initial treatment consisted
of subcutaneous LMWH or subcutaneous LMWH plus warfarin.
Among trials including only participants with symptomatic PE
(Beckman 2003; Kucher 2005; Perez-de-Llano 2010), Beckman
2003 compared different initial treatments, but Kucher 2005 and
Perez-de-Llano 2010 provided the same initial treatment, that is,
subcutaneous LMWH. One trial included participants with both
symptomatic DVT and symptomatic PE (Massicotte 2003) and
provided different initial treatment for the two treatment groups.
Pini 1994 followed all participants for the entire follow-up period
and performed intention-to-treat analysis. Das 1996 reported that
a total of 19 participants (18%) did not complete the trial accord-
ing to the protocol; six participants in the LMWH group did not
complete the three months of follow-up (one death, one severe
illness, two PE, one loss to follow-up, one inadequate venogram);
13 participants in the VKA group did not complete the three
months of follow-up (three deaths, three severe illness, one PE,
three losses to follow-up, three inadequate venograms); and analy-
ses of participant data were based on an intention-to-treat analysis.
Gonzalez 1999 excluded 20 (11%) participants from the analysis:
eight participants in the LMWH arm and 12 in the vitamin K
antagonist arm. Investigators did not provide results of intention-
to-treat analysis nor outcome data (in total, 12 participants had
no second venogram, five participants received treatment that was
not conducted properly, and three participants were lost to follow-
up). Lopaciuk 1999 excluded a total of nine participants after ran-
domisation and performed no intention-to-treat analyses. Three
participants in the LMWH group (one sudden death during ini-
tial treatment, one PE (day three) and vena caval filter insertion
(day 14), and one initial treatment changed to unfractionated hep-
arin) and six in the VKA group (two with an exclusion criterion
overlooked (vein compression by arterial aneurysm), three consent
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withdrawals, and one initial treatment changed to thrombectomy)
did not complete the trial according to the protocol. Kakkar 2003
reported that 54 participants were not included in the intention-
to-treat analysis (evenly divided over the three treatment arms), six
participants did not have a baseline venography, and in 48 partici-
pants symptomatic DVTwas not confirmed independently by the
baseline venogram. Daskalopoulos 2005 reported that a total of
six participants were excluded before commencement of treatment
(five in the LMWH arm and one in the VKA arm). Hull 2007
reported that a total of six participants did not complete the trial
according to the protocol and provided intention-to-treat analysis
of data for these participants. In the VKA arm, four participants
did not complete the trial (one was lost to follow-up and three
withdrew consent); and in the LMWH arm, two participants did
not complete the trial (one was lost to follow-up and one withdrew
consent).Hull 2009 reported that 3 of 480participantswere lost to
follow-up at 12 months (1 in the heparin group and 2 in the usual
care group). Perez-de-Llano 2010 reported that eight participants
did not complete the study protocol successfully; five participants
(9.7%) randomised to heparin (metastatic cancer, allergy to hep-
arin, vein thrombosis, and two unknown reasons) and three (6%)
to VKA (metastatic cancer, inability to reach therapeutic INR, and
one unknown reason). Hamann 1998, Veiga 2000, Lopez 2001,
Beckman 2003, Kucher 2005, and Romera 2009 reported that all
trial participants were followed-up. Massicotte 2003 reported use
of intention-to-treat analyses but excluded two participants - one
from each group, who did not receive study medications - from
these analyses. Two participants failed to meet inclusion criteria
and two failed to meet exclusion criteria, but these participants
did receive study medications and were left in the intention-to-
treat analyses. Massicotte 2003 reported that eight participants
(including one death) in the LMWH group and 14 (including 4
deaths) in the unfractionated heparin group withdrew from the
study.
All included studies provided aminimum of threemonths of treat-
ment. Three studies reported a treatment period of six months
(Daskalopoulos 2005; Perez-de-Llano 2010; Romera 2009), and
in three other studies some participants received three months of
treatment and others six months of treatment (Hamann 1998;
Lopez 2001; Veiga 2000). A total of 12 studies reported additional
follow-up after cessation of treatment ranging from 28 days to
9 months (Daskalopoulos 2005; Gonzalez 1999; Hamann 1998;
Hull 2007;Hull 2009; Kakkar 2003; Lopaciuk 1999; Lopez 2001;
Massicotte 2003; Pini 1994; Romera 2009; Veiga 2000).
Seven trials described quality of treatment with VKAs, defined
as INR between 2.0 and 3.0 (Das 1996; Daskalopoulos 2005;
Gonzalez 1999; Lopez 2001; Perez-de-Llano 2010; Pini 1994;
Veiga 2000); percentages are given in the Characteristics of
included studies table. Beckman 2003 and Hull 2007 provided
INRs for participants who had a major bleeding complication.
Romera 2009 provided INRs for some of the participants with
bleeding complications.
Excluded studies
In total, we excluded four studies. Reasons for exclusion included
the following.
• Non-randomised trial (Vorobyeva 2009).
• Composite endpoint trial (Ghirarduzzi 2009).
• Subjective reporting (Hull 2001; Hull 2001a).
Risk of bias in included studies
See Figure 2 and Figure 3 for graphical presentations of risk of
bias. Lack of detail was the main reason for the ’unclear’ rating for
most trials.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Nine trials described the method used to generate the random
allocation sequence in sufficient detail, indicating low risk of bias
(Das 1996; Daskalopoulos 2005; Gonzalez 1999; Hull 2007;Hull
2009; Kucher 2005; Massicotte 2003; Perez-de-Llano 2010; Pini
1994). The randomisation method was unclear in seven trials (
Beckman 2003; Hamann 1998; Kakkar 2003; Lopaciuk 1999;
Lopez 2001; Romera 2009; Veiga 2000).
Only three trials adequately concealed allocation (Das 1996;
Lopaciuk 1999; Veiga 2000). We determined that the remaining
13 trials had unclear risk of bias (Beckman 2003; Daskalopoulos
2005; Gonzalez 1999; Hamann 1998; Hull 2007; Hull 2009;
Kakkar 2003; Kucher 2005; Lopez 2001; Massicotte 2003;
Perez-de-Llano 2010; Pini 1994; Romera 2009).
Blinding
All included trials were at high risk of performance bias because
they were open-label trials.
Eleven trials were at low risk of detection bias because they re-
ported adequate blinding of outcome assessments (Das 1996;
Daskalopoulos 2005; Gonzalez 1999; Hull 2007; Hull 2009;
Kakkar 2003; Lopez 2001; Massicotte 2003; Pini 1994; Romera
2009; Veiga 2000). Two trials were at high risk of detection bias
because they did not report blinded outcome assessment (Kucher
2005; Lopaciuk 1999); and three trials were at unclear risk of
bias because it was unclear whether those collecting outcomes
data were aware of the allocation (Beckman 2003; Hamann 1998;
Perez-de-Llano 2010).
Incomplete outcome data
Risk of bias was low for 15 trials, as investigators followed-
up and reported on all participants (Beckman 2003; Das 1996;
Daskalopoulos 2005; Gonzalez 1999; Hamann 1998; Hull 2007;
Hull 2009; Kucher 2005; Lopaciuk 1999; Lopez 2001;Massicotte
2003; Perez-de-Llano 2010; Pini 1994; Romera 2009; Veiga
2000). We classified only Kakkar 2003 as having high risk of bias,
as investigators did not follow up on 33% of randomised partici-
pants, as was required by the trial design.
Selective reporting
Fourteen trials were at low risk of bias, and two trials (Das 1996;
Hamann 1998) had unclear risk of bias owing to insufficient in-
formation provided in trial reports.
Other potential sources of bias
Nine trials were free of other sources of bias (Beckman 2003; Das
1996; Kakkar 2003; Kucher 2005; Lopez 2001; Perez-de-Llano
2010; Pini 1994; Romera 2009; Veiga 2000). However, one trial
was at unclear risk, as investigators provided insufficient informa-
tion (Hamann 1998).We deemed Lopaciuk 1999 to be at unclear
risk of other bias because study authors did not discuss three fatal
peripheral or cardiovascular events in the acenocoumarol group,
and because follow-up treatments after planned three-month out-
comes differed between groups. Five (category I) trials had un-
clear risk, as results may have been confounded by differences in
the initial treatment (Daskalopoulos 2005; Gonzalez 1999; Hull
2007; Hull 2009; Massicotte 2003).
Effects of interventions
See: Summary of findings for the main comparison LMWH
compared withVKA for long term treatment of symptomatic VTE
Incidence of recurrent venous thromboembolism
during active treatment
All 16 trials reported the occurrence of recurrent symptomatic
VTE during the first three months after randomisation.
A total of 86 of 1702 participants (5.1%) in the VKA group
had recurrent symptomatic VTE versus 70 of 1597 participants
(4.4%) in the LMWH group. Pooled analysis showed no clear dif-
ferences between treatment modalities for recurrent symptomatic
VTE (Peto OR 0.83, 95% CI 0.60 to 1.15; P = 0.27; 3299 partic-
ipants; 16 studies; moderate-quality evidence) among participants
with symptomatic VTE. Heterogeneity was assessed as I2 = 9%
(Analysis 1.1; Figure 4).
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Figure 4. Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment
(category I and II trials); outcome: 2.1 incidence of recurrent VTE.
Although 15 trials showed no clear differences in recurrent VTE
between LMWH and VKA treatment, one trial (Gonzalez 1999)
found a difference in favour of LMWH treatment (Peto OR 0.38,
95% CI 0.17 to 0.86; 185 participants).
Twelve trials included only participants with symptomatic DVT.
In these trials, a total of 82 of 1572 participants (5.2%) in the
VKA group had recurrent symptomatic VTE versus 63 of 1449
participants (4.3%) in the LMWH group, showing no clear dif-
ferences between treatment modalities for recurrent symptomatic
VTE (Peto OR 0.79, 95% CI 0.57 to 1.11; P = 0.18; 3021 par-
ticipants; 12 studies) among participants with symptomatic DVT.
Heterogeneity was assessed as I2 = 8% (Analysis 2.1).
In contrast, among the three trials including only participants
with symptomatic PE, none of 90 participants (0%) in the VKA
group had recurrent symptomatic VTE versus 5 of 112 partici-
pants (4.5%) in the LMWH group, resulting in no clear differ-
ences between treatments for episodes of recurrent symptomatic
VTE (Peto OR 5.70, 95% CI 0.91 to 35.60; P = 0.06; 202 partic-
ipants; three studies) among participants with symptomatic PE.
Heterogeneity was assessed as I2 = 0% (Analysis 3.1).
Consideration of category I trials (Das 1996;Daskalopoulos 2005;
Gonzalez 1999; Hull 2007; Hull 2009; Massicotte 2003; Pini
1994) revealed that six trials included only participants with symp-
tomatic DVT and the remaining trial (Massicotte 2003) included
participants with both symptomatic DVT and PE. A total of 61
of 941 participants (6.5%) in the VKA arm had recurrent symp-
tomatic VTE versus 49 of 931 participants (5.3%) allocated to
LMWH treatment during three months of treatment. Analysis of
pooled data showed no clear differences between treatmentmodal-
ities for recurrent symptomatic VTE (Peto OR0.80, 95%CI 0.54
to 1.18; P = 0.26; 1872 participants; seven studies). Heterogeneity
was assessed as I2 = 16% (Analysis 4.1).
Five category I trials may have been confounded by differences
in initial treatment (Daskalopoulos 2005; Gonzalez 1999; Hull
2007; Hull 2009; Massicotte 2003). Analysing these trials sepa-
rately revealed no clear differences between treatment groups (Peto
OR 0.68, 95% CI 0.44 to 1.03; P = 0.07; 1580 participants; five
studies). Heterogeneity was assessed as I2 = 0% (Analysis 6.1). We
considered in a separate analysis the two category I trials that com-
pared a VKA versus LMWH for long term treatment of symp-
tomatic VTE, using the same initial treatment in both arms (Das
1996; Pini 1994). Analysis of pooled data showed no clear dif-
ferences in recurrent symptomatic VTE between treatments (Peto
OR 1.95, 95% CI 0.74 to 5.19; P = 0.18; 292 participants; two
studies). Heterogeneity was assessed as I2 = 0% (Analysis 5.1).
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Incidence of recurrent symptomatic venous
thromboembolism during the additional period of
follow-up after cessation of active treatment
Five category I trials (Daskalopoulos 2005; Gonzalez 1999; Hull
2007; Hull 2009; Pini 1994) and five category II trials (Hamann
1998; Lopaciuk 1999; Lopez 2001; Romera 2009; Veiga 2000)
evaluated a period of six to nine months after cessation of the al-
located treatment. A total of 53 of 1296 participants (4.1%) in
the VKA group versus 59 of 1296 participants (4.6%) in the arm
allocated to LMWH treatment experienced an episode of recur-
rent symptomatic VTE. Combined analysis showed no clear dif-
ferences in recurrent symptomatic VTE between treatment arms
(Peto OR 1.12, 95% CI 0.77 to 1.64; P = 0.56; 2592 participants;
10 studies). Heterogeneity was assessed as I2 = 28% (Analysis 7.1).
A separate analysis for the category I trials (Daskalopoulos 2005;
Gonzalez 1999; Hull 2007; Hull 2009; Pini 1994) evaluating an
additional period of nine months after cessation of the allocated
treatment resulted in a total of 36 of 846 participants (4.3%) in the
VKA arm versus 45 of 845 participants (5.3%) in the LMWHarm
experiencing an episode of recurrent symptomatic VTE. Com-
bined analysis showed no clear differences in thromboembolic
complications between treatment modalities (Peto OR 1.26, 95%
CI 0.81 to 1.98; P = 0.30; 1691 participants; five studies). Het-
erogeneity was assessed as I2 = 14% (Analysis 8.1). It should be
noted that in Pini 1994, 34 of 94 participants used the VKA dur-
ing an additional three months and 14 of 94 participants used
the VKA for an additional nine months, whereas in the LMWH
group all 93 participants stopped assigned treatment after three
months. Furthermore, in Hull 2007, 250 of 368 participants in
the VKA allocated treatment arm were treated with LMWH be-
yond the three months of allocated treatment and in the LMWH
group 146 of 369 participants continued allocated treatment be-
yond the three months of allocated treatment. Hull 2009 reported
that some participants in both treatment groups received ongoing
warfarin after the first three months of allocated treatment.
The total 12-month period of follow-up (combining threemonths
of active treatment and nine months of follow-up) among five
category I trials (Daskalopoulos 2005; Gonzalez 1999; Hull 2007;
Hull 2009; Pini 1994) included a total of 91 of 846 participants
(10.8%) in the VKA group versus 87 of 845 participants (10.3%)
in the LMWH group who had recurrent symptomatic VTE and
showed no clear differences between treatment modalities for risk
of recurrent symptomatic VTE (Peto OR 0.95, 95% CI 0.70 to
1.30; P = 0.75; 1691 participants; five studies) among participants
with symptomatic PE. Heterogeneity was assessed as I2 = 58%
(Analysis 10.1).
Analysis of pooled data from 10 category I and category II trials
(Daskalopoulos 2005; Gonzalez 1999;Hamann 1998;Hull 2007;
Hull 2009; Lopaciuk 1999; Lopez 2001; Pini 1994; Romera 2009;
Veiga 2000) showed no clear differences between LMWH and
VKA treatment for the total 12-month period of follow-up (Peto
OR 0.88, 95% CI 0.67 to 1.15; P = 0.34; 2592 participants; 10
studies). Heterogeneity was assessed as I2 = 41% (Analysis 9.1).
Incidence of major bleeding during active treatment
All 16 category I and II trials reported the incidence of major
bleeding during allocated treatment. Thirteen trials found no clear
differences and only two trials found differences between groups
(Beckman 2003; Lopez 2001). Lopez 2001 found a difference that
favoured the LMWHgroup (PetoOR0.12, 95%CI 0.02 to 0.89).
This trial included only participants with DVT. Beckman 2003
found a difference that favoured the LMWH group (Peto OR
0.05, 95% CI 0.00 to 0.92). This trial included only participants
with symptomatic PE.
Analysis of pooled trials showed major bleeding complications
among 50 of 1702 participants (2.9%) in the VKA arm versus 25
of 1597 participants (1.6%) in the LMWH group. This difference
favoured LMWH therapy for the outcome ofmajor bleeding (Peto
OR 0.51, 95% CI 0.32 to 0.80; P = 0.004; 3299 participants; 16
studies; low-quality evidence). Heterogeneity was assessed as I2 =
0% (Analysis 1.2; Figure 5).
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Figure 5. Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment
(category I and II trials); outcome: 2.2 incidence of major bleeding.
Analysing the 12 trials that included only participants with symp-
tomatic DVT revealed that a total of 42 of 1572 participants
(2.7%) in the VKA group had major bleeding versus 22 of 1449
participants (1.5%) in the LMWH group, showing a difference
between treatment modalities that favoured LMWH for the out-
come of major bleeding (Peto OR 0.54, 95% CI 0.33 to 0.88; P
= 0.01; 3021 participants; 12 studies) among participants treated
with symptomatic DVT. Heterogeneity was assessed as I2 = 0%
(Analysis 2.2).
The three trials (Beckman 2003; Kucher 2005; Perez-de-Llano
2010) that included only participants with symptomatic PE ob-
served major bleeding in a total of 3 of 90 participants (3.3%)
in the VKA group versus 1 of 112 participants (0.9%) in the
LMWH group, revealing no clear differences between treatments
for the outcome of major bleeding (Peto OR 0.23, 95% CI 0.03
to 1.78; P = 0.16; 202 participants; three studies) among partici-
pants treated for symptomatic PE. Heterogeneity was assessed as
I2 = 52% (Analysis 3.2).
Consideration of only category I trials (Das 1996; Daskalopoulos
2005; Gonzalez 1999; Hull 2007; Hull 2009; Massicotte 2003;
Pini 1994) revealed that a total of 34 of 941 participants (3.6%)
in the VKA arm versus 21 of 931 participants (2.3%) allocated
to LMWH treatment experienced major bleeding during three
months of treatment. Analysis of pooled data showed no clear
differences between treatmentmodalities for the outcome ofmajor
bleeding (Peto OR 0.62, 95% CI 0.36 to 1.07; P = 0.08; 1872
participants; seven studies). Heterogeneity was assessed as I2 = 0%
(Analysis 4.2).
We performed post hoc analyses to assess the subsets of participants
with fatal haemorrhage and intracranial haemorrhage to deter-
mine how LMWH and VKA differ with respect to severe bleeds.
We found no clear differences between LMWH and VKA among
combined category I and category II studies and in category I
studies only (results not shown).
For two category I trials providing the same initial treatment in
both groups (Das 1996; Pini 1994) analysis of data showed no ev-
idence of a difference in major bleeding incidence between treat-
ment modalities (Peto OR 1.01, 95% CI 0.20 to 5.12; P = 0.99;
292 participants; two studies; I2 = not applicable) (Analysis 5.2).
For five category I trials providing different initial treatments in
the two groups (Daskalopoulos 2005; Gonzalez 1999; Hull 2007;
Hull 2009; Massicotte 2003) analysis of data showed no clear dif-
ferences between treatment modalities (Peto OR 0.59, 95% CI
0.33 to 1.04; P = 0.07; 1580 participants; five studies; I2 = 0%)
(Analysis 6.2).
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Incidence of major bleeding during the additional
period of follow-up after cessation of active treatment
No major bleeding occurred during the additional nine months
of follow-up (Analysis 7.2; Analysis 8.2).
Analysis of pooled data in nine category I and category II tri-
als (Daskalopoulos 2005; Gonzalez 1999; Hamann 1998; Hull
2007; Lopaciuk 1999; Lopez 2001; Pini 1994; Romera 2009;
Veiga 2000) for the total 12 months of follow-up showed major
bleeding complications in 36 of 1056 participants (3.4%) in the
VKA arm versus 20 of 1056 participants (1.9%) in the LMWH
group. This difference was in favour of LMWH therapy (Peto OR
0.56, 95% CI 0.33 to 0.95; P = 0.03; 2112 participants; nine
studies). Heterogeneity was assessed as I2 = 0% (Analysis 9.2).
The 12-month period of follow-up (combining three months ac-
tive treatment and nine months follow-up) in four category I trials
(Daskalopoulos 2005; Gonzalez 1999; Hull 2007; Pini 1994) in-
cluded a total of 25 of 606 participants (4.1%) in the VKA group
versus 18 of 605 participants (3.0%) in the LMWH group who
had a major bleeding incident, and showed no clear differences
between treatment modalities (Peto OR 0.72, 95% CI 0.39 to
1.32; P = 0.28; 1211 participants; four studies). Heterogeneity
was assessed as I2 = 0% (Analysis 10.2).
Mortality during active treatment
All 16 trials reported mortality during allocated treatment with
no clear differences between treatment groups. Fifty-nine of 1702
participants (3.5%) in the VKA treatment group died versus 62 of
1597 participants (3.9%) in the LMWH group, which produced
a pooled Peto OR of 1.08 (95% CI 0.75 to 1.56; P = 0.68; 3299
participants; 16 studies; moderate-quality evidence). Heterogene-
ity was assessed as I2 = 0% (Analysis 1.3; Figure 6). We obtained
similar results when pooling only category I trial data (Peto OR
0.92, 95% CI 0.61 to 1.41; P = 0.71; 1872 participants; seven
studies). Heterogeneity was assessed as I2 = 0% (Analysis 4.3).
Figure 6. Funnel plot of comparison: 2 LMWH versus VKA during three months of allocated treatment
(category I and II trials), outcome; 2.3 mortality.
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For two category I trials providing the same initial treatment for
both groups (Das 1996; Pini 1994) andfive category I trials provid-
ing different initial treatments for the two groups (Daskalopoulos
2005; Gonzalez 1999; Hull 2007; Hull 2009; Massicotte 2003),
pooled analyses did not show a clear difference in mortality be-
tween treatment modalities (Peto OR 0.89, 95% CI 0.29 to 2.68;
P = 0.83; 292 participants; two studies; I2 = 0% (Analysis 5.3); and
Peto OR 0.93, 95% CI 0.59 to 1.46; P = 0.76; 1580 participants;
five studies; I2 = 0% (Analysis 6.3)).
For the 12 trials that considered participants withDVTand for the
three trials that considered participants with PE, analysis revealed
no clear differences in mortality between treatment modalities
(Peto OR 1.10, 95% CI 0.75 to 1.60; P = 0.64; 3021 participants;
12 studies; I2 = 0% (Analysis 2.3); and Peto OR 5.39, 95% CI
0.51 to 57.36; P = 0.16; 202 participants; three studies; I2 = 0%
(Analysis 3.3)).
Mortality during the additional period of follow-up
after cessation of active treatment
Five category I and five category II trials (Daskalopoulos 2005;
Gonzalez 1999; Hamann 1998; Hull 2007; Hull 2009; Lopaciuk
1999; Lopez 2001; Pini 1994; Romera 2009; Veiga 2000) reported
an extended follow-up period for an additional six to nine months
and found that 72 of 1296 participants (5.6%) in the VKA arm
versus 72 of 1296 participants (5.6%) in the LMWH group (Peto
OR 1.00, 95% CI 0.71 to 1.40; P = 1.00; 2592 participants; 10
studies) died.Heterogeneity was assessed as I2 = 0% (Analysis 7.3).
We obtained similar results when considering only category I trials
(Peto OR 1.06, 95% CI 0.72 to 1.55; P = 0.77; 1691 participants;
five studies; I2 = 0%) (Analysis 8.3).
Analysis of mortality for the total 12-month follow-up period did
not detect a clear difference between treatment modalities for the
10 category I and category II trials (Peto OR 1.09, 95% CI 0.84
to 1.43; P = 0.51; 2592 participants; 10 studies; I2 = 0% (Analysis
9.3)) nor for the five category I trials (Peto OR 1.05, 95% CI 0.78
to 1.42; P = 0.76; 1691 participants; five studies; I2 = 0% (Analysis
10.3)).
D I S C U S S I O N
Summary of main results
This review detected no clear differences between low-molecu-
lar-weight heparin (LMWH) and vitamin K antagonists (VKAs)
for two of the three primary outcomes (recurrent symptomatic
venous thromboembolism (VTE) and overall mortality). For the
third outcome, major bleeding, data show a reduction in favour
of LMWH (Peto odds ratio (OR) 0.51, 95% confidence interval
(CI) 0.32 to 0.80; P = 0.004). However, pooling of data from
category I trials alone (clearly concealed randomisation, double-
blind or blinded outcome assessment) revealed no clear differences
in major bleeding between treatment groups (Peto OR 0.62, 95%
CI 0.36 to 1.07; P = 0.08). Although this review found no evi-
dence that LMWH has greater efficacy than VKAs for long term
treatment of VTE, evidence shows that long term treatment of
symptomatic VTE with LMWH versus long term treatment with
VKAs may be safer with respect to major bleeding. The largest
trial (Hull 2007) reported no clear differences for any of the three
outcomes. Results were similar for recurrent symptomatic VTE,
major bleeding, and mortality during an additional six to nine
months after cessation of the allocated three months of treatment
for symptomatic VTE.
In interpreting the findings of this review, one must consider sev-
eral points. Five category I trials did not use the same initial treat-
ment in both treatment arms, and these differences may threaten
the validity of data derived from these trials (Daskalopoulos 2005;
Gonzalez 1999; Hull 2007; Hull 2009; Massicotte 2003). A pre-
vious report suggests that the inferior quality of initial unfraction-
ated heparin treatment may be associated with higher recurrence
of VTE during follow-up (Hull 1997), and two trials included in
the review did not report the quality of unfractionated heparin
treatment (Daskalopoulos 2005; Gonzalez 1999). In the largest
trial (Hull 2007), initial treatment with unfractionated heparin
was adequate but produced no differences in effect between treat-
ment modalities. Doses of the various LMWH compounds used
in individual trials ranged from 100 IU/kg reviparin sodium to
175 anti-Xa IU/kg tinzaparin and 4000 anti-Xa IU enoxaparin.
Daskalopoulos 2005 and Hull (Hull 2007; Hull 2009) used the
same dose of LMWH for both initial and long term treatment of
symptomatic VTE. Massicotte 2003 recruited only children and
adjusted the dose accordingly. These five category I trials found
no clear difference in the incidence of recurrent VTE between
LMWH and VKAs (Peto OR 0.68, 95% CI 0.44 to 1.03; P =
0.07).
In contrast, the two category I trials that provided the same ini-
tial treatment for both treatment arms observed a trend in favour
of VKAs for prevention of recurrent symptomatic VTE when us-
ing relatively low doses of LMWH during long term treatment
of deep vein thrombosis (DVT) (Das 1996; Pini 1994); dosages
were approximately twice those normally used for prophylaxis of
symptomatic VTE and were not adjusted for weight. The rela-
tively low dose used is reflected in the very low levels of anti-Xa
activity found after 22 hours (0.04 U/mL after injection of 4000
anti-Xa IU enoxaparin) (Pini 1994).
Lopez 2001 included 25 participants (14 participants in the
LMWH treatment group and 11 in the VKA treatment group; n
= 158) with infrapopliteal DVT (calf vein thrombosis) diagnosed
by duplex ultrasonography. Excluding these data from the sensi-
tivity analysis did not affect findings. Two considerations are of
interest here. First, duplex ultrasonography is not as sensitive and
specific for distal thrombosis as it is for proximal DVT (Mitchell
1991). Second, the natural history of distal DVT is unclear. It is
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estimated, from trials of diagnosis, that approximately only 20%
of calf vein thrombi develop into a proximal DVT within two
weeks of presentation, whereas the remainder, which probably are
small and self-limiting, do not (Heijboer 1993; Huisman 1986;
Huisman 1989; Hull 1985).
The difference inmajor bleeding complications favouringLMWH
during allocated treatment of three months has to be considered
with caution. Different LMWH compounds and relatively low
doses of medication were used, as has been mentioned. Although
a difference in bleeding incidence favouring LMWH was found
when all trials were combined (Peto OR 0.51, 95% CI 0.32 to
0.80; P = 0.004), no clear difference between LMWH and VKA
was observed (PetoOR0.62, 95%CI 0.36 to 1.07; P = 0.08) when
only category I trials were considered. These trials used higher
dosages of LMWH. On the other hand, the only trial that found
a difference in favour of LMWH treatment used the same dose of
LMWH for initial treatment as for long term treatment of symp-
tomaticDVT (PetoOR0.12, 95%CI 0.02 to 0.89) (Lopez 2001).
Post hoc analyses showed no clear differences between LMWH and
VKA when subsets of fatal and intracranial haemorrhage were as-
sessed.
Overall, the data show no substantial differences in efficacy for
long term treatment of patients withDVTwith LMWHor VKAs,
but long term treatment with LMWH may cause fewer episodes
of major bleeding than occur with VKA therapy.
Currently, many patients are treated at home with a course of
subcutaneous LMWH administered by the patients themselves.
After this initial treatment, patients continue with a three-month
course of VKA with the dose adjusted to achieve an international
normalised ratio (INR) between 2.0 and 3.0. Treatments used
in Das 1996 and Daskalopoulos 2005 do not represent current
practice.
Important practical considerations involving mainly patient and
local preferences also influence the choice between LMWH and
VKAs. The major disadvantage of VKA treatment compared with
LMWH treatment is the need for regular laboratory monitoring.
Furthermore, VKA compounds have some major drug interac-
tions, but drug interactions of LMWH are uncommon. In addi-
tion, treatment with LMWH is relatively safe during pregnancy
(Sanson 1999). A major disadvantage of treatment with LMWH
is that the patient has to self-administer subcutaneous injections
on a daily basis. Among the included trials, only a few participants
stopped treatment with LMWH, mainly as the result of prob-
lems other than administration of subcutaneous injections. Das
1996 reported that 8% of patients refused to participate in the
trial because of reluctance to administer subcutaneous injections
by themselves.
Overall completeness and applicability of
evidence
Participants with symptomatic VTE included in these trials con-
stituted a representative mix of people with this disease. All trials
included approximately similar participants; therefore, these data
can be generalised to the wider population. Several published tri-
als included only participants with a diagnosis of cancer who had
symptomatic VTE. We did not include these trials in our review
because participants do not represent the normal cohort of pa-
tients with a diagnosis of symptomatic VTE, and because this is
the topic of another Cochrane review (Akl 2014).
Only scant data have been gathered on patients with symptomatic
pulmonary embolisation (PE). This review includes data fromonly
202 people with PE, and review findings should be interpreted
with caution.
Direct oral anticoagulants (DOACs) are changing theways that pa-
tients are treated (Robertson 2015; Robertson 2015b). Therefore,
in the future, as more andmore patients are prescribedDOACs in-
stead of VKA and LMWH, the analysis performed for this review
may become outdated. We will reconsider the focus and future of
this review in future updates.
Quality of the evidence
Fifty-nine per cent of included patients (1872/3299) participated
in trials with category I classification yielding evidence of highest
quality on direct treatment comparisons.
All randomised controlled trials included in this systematic re-
view were conducted in an unblinded manner because the two
different interventions were delivered in different settings (hos-
pital and home), making participant blinding impossible. When
participant outcomes were assessed by individuals who were blind
to treatment allocation, we considered threats to the validity of
trial conclusions to be reduced. When it was not reported that
those collecting outcome measures data were unaware of treat-
ment allocation, trial findings may have been compromised. Trials
in which allocation is not concealed and outcomes are not col-
lected in a blind manner are essentially observational rather than
experimental in nature. Analysis for only category I trials (clearly
concealed randomisation, double-blind or blinded outcome as-
sessment) shows similar results to those of analyses for all studies
combined, except for bleeding, which showed no clear differences
between treatment groups.
We downgraded the quality of evidence for recurrent VTE and
mortality to moderate owing to imprecision resulting from the
small number of events and the relatively large confidence inter-
val. We decided not to downgrade for risk of bias due to blind-
ing because a sensitivity analysis excluding studies deemed of low
methodological quality confirmed no clear differences between
LMWH and VKA.
We downgraded the quality of evidence for major bleeding to low
owing to risk of bias and inconsistency: a sensitivity analysis in-
cluding only category I trials (clearly concealed randomisation,
double-blind or blinded outcome assessment) showed no clear dif-
ferences between VKA and LMWH. Bleeding outcomes are more
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susceptible to biased outcome reporting than outcomes such as
VTE and mortality, and only two studies (studies of low method-
ological quality) have reported less bleeding with LMWH; the re-
mainder showed no clear differences because confidence intervals
crossed the line of no effect. See Summary of findings for the main
comparison.
Potential biases in the review process
Methods used to conduct this review are described in detail in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011); particular strengths include independent application of re-
view eligibility criteria, independent data extraction and assess-
ment of risk of bias, and assessment of quality of evidence accord-
ing to GRADE. The Cochrane Vascular Information Specialist,
who is highly skilled in identification of randomised controlled
trials, devised and conducted the search strategies. We are confi-
dent that we have included all relevant studies. However, the pos-
sibility remains that some relevant trials, particularly in the ’grey’
literature (e.g. conference proceedings), have been missed. Other
potential biases in the review process are the missing information
from three trials regarding aspects of their conduct (Massicotte
2003; Pini 1994; Romera 2009).
Agreements and disagreements with other
studies or reviews
Three published systematic reviews have previously evaluated
VKAs versus LMWH(Bochenek 2012; Ferretti 2006; Iorio 2003).
Two reviews did not find a clear difference between LMWH and
oral anticoagulants (Ferretti 2006; Iorio 2003).
Iorio 2003 reviewed the efficacy and safety of long term treatment
of VTE with LMWH compared with oral anticoagulants and did
not find a clear difference between treatment types in terms of
assessment of recurrent VTE (odds ratio (OR) 0.66, 95% CI 0.41
to 1.07), major bleeding (OR 0.45, 95% CI 0.18 to 1.11), or total
mortality (OR 1.19, 95% CI 0.78 to 1.83). This meta-analysis
included six trials (Das 1996; Gonzalez 1999; Lopaciuk 1999;
Lopez 2001; Pini 1994; Veiga 2000) and one abstract (Hull 2000).
We included all trials in our review except Hull 2000, which is a
duplicate report (conference abstract) of the included trial Hull
2007.
Ferretti 2006 reviewed only recurrent VTE after treatment with
LMWH compared with oral anticoagulants for people with VTE
and found no clear differences between treatments when assessing
recurrent symptomatic VTE (OR 1.29, 95% CI 0.82 to 2.02).
This meta-analysis included three trials of patients with cancer,
which we excluded for the purpose of this Cochrane review, three
other trials that we judged to be of high methodological quality
(Das 1996; Gonzalez 1999; Pini 1994), four that we considered
of lower methodological quality (Kakkar 2003; Lopaciuk 1999;
Lopez 2001; Veiga 2000), and an abstract (Hull 2002) of the
included trial Hull 2007.
The third systematic review did detect a difference between treat-
ments. Bochenek 2012 reviewed the efficacy and safety of long
term treatment of VTE with LMWH compared with oral an-
ticoagulants and found a reduction in episodes of VTE (OR
0.75, 95% CI 0.59 to 0.97) and in the outcome major bleed-
ing (OR 0.59, 95% CI 0.47 to 0.74). This review did not eval-
uate mortality as an outcome. The Bochenek 2012 review in-
cluded six trials that we judged to be of high methodological qual-
ity (Das 1996; Daskalopoulos 2005; Gonzalez 1999; Hull 2007;
Massicotte 2003; Pini 1994) and six trials that we judged to be
of lower methodological quality (Beckman 2003; Kakkar 2003;
Kucher 2005; Lopaciuk 1999; Lopez 2001; Veiga 2000). The
meta-analysis by Bochenek 2012 included two trials that consid-
ered only patients with cancer, who were excluded for the purpose
of this Cochrane review. One of these studies showed a significant
effect of LMWHheavily influencing the overall outcome and con-
tributing approximately one-third of the overall weight; this was
likely the reason for the difference between Bochenek 2012 and
the current Cochrane review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence shows no clear differences between
LMWH and VKA in preventing symptomatic VTE and mortal-
ity after an episode of symptomatic DVT. Low-quality evidence
suggests fewer cases of major bleeding with LMWH than with
VKA. However, when only high-quality studies are compared for
bleeding, no clear difference between LMWH and VKA is evi-
dent. LMWH may present an alternative for some patients, for
example, those in geographically inaccessible areas, those who are
reluctant or unable to visit the thrombosis service regularly, and
those with contraindications to VKAs. Only limited data are avail-
able for patients with symptomatic PE.
Implications for research
For more definitive conclusions, additional adequately designed
randomised controlled clinical trials are needed, especially in the
field of symptomatic PE. These trials must include patients with
contraindications for VKAs (e.g. pregnant women), patients who
are unable or reluctant to go to the thrombosis service on a regular
basis, and patients living in geographically inaccessible areas.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Beckman 2003
Methods Randomised parallel-design single-institution treatment trial
Participants Patients (40 allocated to LMWH (20 patients 1.5 mg/kg daily and 20 patients 1.0 mg/
kg daily) and 20 to VKA treatment) with PE confirmed on high-probability ventilation-
perfusion scanning, a positive spiral chest computed tomogram or a conventional pul-
monary angiogram, or an intermediate ventilation-perfusion lung scan in the presence
of high clinical suspicion of PE
Age, mean ± SD, years: LMWH 55 ± 13/VKA 56 ± 11
Gender, %F: LMWH 75/VKA 70
Location: 1 centre in USA
Interventions The warfarin arm comprised of a course of continuous infusion intravenous unfrac-
tionated heparin for a minimum of 5 days and concomitant warfarin for 90 days. The
enoxaparin arm started with a course of 14 days of 1 mg/kg twice-daily, followed by
either a course of 1.5 mg/kg once-daily, enoxaparin (20 participants), or a course of 1.0
mg/kg once-daily enoxaparin (20 participants). All participants in the enoxaparin arm
received a total of 90 days of enoxaparin. Randomisation into the enoxaparin categories
was performed at beginning of trial when participants were initially assigned to enoxa-
parin or standard/warfarin therapy
Outcomes Recurrent VTE/DVT: loss of vein compressibility demonstrated on ultrasound
PE: positive spiral computed tomogram
Major bleeding: clinically overt and associated with a fall in haemoglobin ≥ 2 g/dL,
intracranial or pericardial
Mortality data were not provided
Notes Participants with major bleeding during VKA treatment had an INR of 8.2 and 3.2,
respectively
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information about the method
used to generate the randomisation sched-
ule; Brigham and Women’s Hospital
(BWH) Investigational Drug Service ran-
domised study participants
Allocation concealment (selection bias) Unclear risk BWH Investigational Drug Service ran-
domised participants, but how allocation
was concealed is not revealed
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Beckman 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial not blinded: Participants
receiving standard therapy had drug regi-
men administered at the principal investi-
gator’s office; those receiving LMWHwere
treated at a different site and underwent
echocardiography
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear as to whether those collecting out-
comes data were aware of the allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Study authors provided a table detailing the
reason why 7 participants dropped out
Selective reporting (reporting bias) Low risk All intended outcomes were reported
Other bias Low risk None observed
Das 1996
Methods Prospective open single-centre randomised clinical trial
Participants 105 patients (50 allocated to LMWH and 55 to VKA treatment) > 40 years of age with
DVT, confirmed on venography
Age, mean ± SD, years: LMWH 65.3 ± 14.9/VKA 58.6 ± 16.4
Gender, M/F: LMWH 24/26/VKA 23/32
Location: 1 centre in UK
Interventions Warfarin-sodium for 3 months (INR of 2.0 to 3.0) compared with a 3-month course of
subcutaneous Fragmin 5000 anti-Xa units (Kabi 2165 heparin fragment) once daily
Both treatment arms started with 10 days of subcutaneous unfractionated heparin ther-
apy
Outcomes Recurrent VTE/DVT: intraluminal filling defect in a deep vein, demonstrated on repeat
venography at a site not previously involved, and demonstrated on 2 views
PE was confirmed on ventilation-perfusion scanning, and eventually on pulmonary
angiography in case of doubt
Major bleeding: overt bleeding associated with a drop in Hb level≥ 2 g/dL, transfusion
of≥ 2 blood units if required, or intracranial haemorrhage; other cases were classified as
minor
Mortality data were provided
Blinded outcome assessment was provided by radiologists unaware of treatment alloca-
tion
Notes 3 months of randomised treatment without additional follow-up
Mean INR achieved in the warfarin group was 2.65, with 68.6% between 2.0 and 3.0,
22.8% between 3.1 and 4.0, and 8.6% between 1.7 and 1.9
Category I trial
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Das 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A restricted randomisation list using per-
muted blocks was prepared using com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Sealed and sequentially numbered en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open trial, not blind. Compliance of par-
ticipants randomised to LMWHwas mon-
itored
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent and blind outcome assess-
ment by radiologists unaware of treatment
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons are given for each participant who
did not complete the trial
Selective reporting (reporting bias) Unclear risk All intended outcomes were reported, but
timing of outcomes at 2, 4, and 8 weeks
was not presented
Other bias Low risk None observed
Daskalopoulos 2005
Methods Prospective open-label randomised clinical trial
Participants 102 patients (50 allocated to LMWH and 52 to VKA treatment) with an episode of
DVT confirmed on colour duplex ultrasound
Age, mean (range), years: LMWH 59.0 (25 to 91)/VKA 58.2 (23 to 95)
Gender, M/F: LMWH 19/31/VKA 22/30
Location: 1 centre in Greece
Interventions Acenocoumarol arm started with a 5 to 7-day course of unfractionated heparin followed
by acenocoumarol for 6 months (INR 2.0 to 3.0). Tinzaparin group started with a 7 day
course of once-daily subcutaneous tinzaparin 175 anti-Xa IU continued for 6 months
Outcomes Recurrent VTE/DVT: presence of new thrombus in a venous segment not found affected
on baseline duplex ultrasound scan
PE: confirmed on ventilation-perfusion scanning, and eventually on pulmonary angiog-
raphy in case of doubt. In case of a fatal event, presence of pulmonary artery emboli at
autopsy
Major bleeding: overt bleeding associated with a drop in Hb level ≥ 2 g/dL; transfu-
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Daskalopoulos 2005 (Continued)
sion of ≥ 2 blood units, if required; intracranial, intraspinal, intraocular, pericardial, or
retroperitoneal bleeding, or death; or need for permanent discontinuation of treatment
Mortality data were provided
Blinded outcome assessment was provided by specialists not involved in the trial, who
interpreted all objective diagnostic tests
Notes 6 months of randomised treatment with 6 months of additional follow-up
INR values in the acenocoumarol arm were 67.2% between 2.0 and 3.0, 13.6% above
3.0, and 19.1% below 2.0
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived treatment schedule
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label, not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded outcome assessment was provided
by specialists not involved in the trial, who
interpreted all objective diagnostic tests
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs. All data described
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Differences in initial treatment regimens
between groups
Gonzalez 1999
Methods Prospective open single-centre randomised clinical trial
Participants 185 patients (93 allocated to LMWH and 92 to VKA treatment) with a first or second
episode of DVT confirmed on contrast venography (20 excluded from analysis by trialists
(8 LMWH, 12 VKA))
Age, mean (range), years: LMWH 62.7 (19 to 83)/VKA 28.3 (20 to 82)
Gender, M/F: LMWH 41/44/VKA 46/34
Location: 1 centre in Spain
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Gonzalez 1999 (Continued)
Interventions Coumarin arm started with a 5-day course of unfractionated heparin followed by
coumarin for 3 months (INR 2.0 to 3.0). Enoxaparin group started with a 7-day course
of twice-daily subcutaneous enoxaparin 40 mg (4000 anti-Xa IU) and continued with a
3-month course of once-daily enoxaparin 40 mg
Outcomes Recurrent VTE/
DVT: constant intraluminal filling defect in a deep vein not present on the first day
PE: ≥ 1 segmental defect not seen on preceding scan and no abnormality on chest
radiograph or pulmonary angiogram
Major bleeding: intracranial or retroperitoneal or producing a decrease in Hb level ≥ 2
g/dL, sufficient to necessitate discontinuation of treatment or transfusion of ≥ 2 units
of blood
Mortality from all causes
Blinded outcome assessment was provided by 2 blinded observers, who assessed the
outcomes of venograms
Notes 3 months of randomised treatment and an additional 9 months of follow-up. All partic-
ipants stopped after 3 months of treatment
Intensity of VKA therapy was 15% INR < 2.0, 64% INR between 2.0 and 3.0, and 21%
INR > 3.0
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived treatment schedule
Allocation concealment (selection bias) Unclear risk Computer-derived treatment schedule; no
other information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial, not blind. Participants in
the LMWH group were not hospitalised
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded outcome assessment was provided
by 2 blinded observers who assessed out-
comes of venograms
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes presented; no loss to follow-up;
1 participant died of a PE
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Unclear risk Differences in initial treatment regimens
between groups
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Hamann 1998
Methods Prospective open randomised clinical trial
Participants 200 patients (100 allocated to LMWHand 100 toVKA treatment) withDVTconfirmed
on venography
Age, mean (range), years: 58 (18 to 92)
Gender, M/F: 82/118
Location: 1 centre, Germany
Interventions Phenprocoumon for 3 or 6 months (INR 2.0 to 3.0) compared with 3- or 6-month
course of subcutaneous dalteparin-sodium 5000 IU anti-Xa once daily
Outcomes Recurrent VTE
Major bleeding
Blinded outcome assessment was not provided
Notes Different initial therapies were used: 17 participants underwent venous thrombectomy,
18 systemic lysis, 28 regional lysis, and 137 IV unfractionated heparin as initial treatment
Furthermore, 44 participants were treated for 3 months and 156 for 6 months for long
term prevention of recurrent VTE. All interventions were evenly divided between groups
3 or 6 months of randomised treatment and an additional 9 months of follow-up
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported
Selective reporting (reporting bias) Unclear risk Insufficient information
Other bias Unclear risk Insufficient information
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Hull 2007
Methods Multi-centre randomised open-label clinical trial
Participants 737 patients (369 allocated to LMWHand 368 toVKA treatment) withDVTconfirmed
on venography or compression ultrasonography
Age, < 60 years old/≥ 60 years old: LMWH 187/182, VKA 152/217
Gender, M/F: LMWH 207/162, VKA 188/180
Location: 30 centres across Canada
Interventions Warfarin arm started with a 6-day course of unfractionated heparin followed by warfarin
for 3 months (INR 2.0 to 3.0). Tinzaparin group received once-daily subcutaneous
tinzaparin 175 anti-Xa IU/kg of body weight, continued for 3 months
Outcomes Recurrent VTE/
DVT: previously compressible proximal vein segment not compressible on repeat ultra-
sonography or venography demonstrating a constant intraluminal filling defect in the
deep veins not present on the baseline venogram
Recurrent PE: (a) high-probability lung scan finding; (b) non-diagnostic lung scan with
documented new DVT; (c) spiral computed tomography showing thrombus in the cen-
tral pulmonary arteries; (d) pulmonary angiography revealing a constant intraluminal
filling defect or cut-off of a vessel > 2.5 mm in diameter; or (e) PE found at autopsy
Major bleeding: clinically overt and (a) associated with a fall in Hb≥ 2 grams/dL, or (b)
transfusion of ≥ 2 units of blood, or intracranial or retroperitoneal bleeding occurring
in a major joint
Mortality data were provided
Blinded outcome assessment was provided by a central independent adjudication com-
mittee
Notes 3 months of randomised treatment and an additional 9 months of follow-up. In the
tinzaparin arm, 146 participants continued with warfarin treatment after 3 months of
treatment with tinzaparin for a mean of 202 days (median, 258 days). In the warfarin
arm, 250 participants continuedwarfarin treatment after 3months of allocated treatment
for a mean of 156 days (median, 147 days)
Participants with major bleeding complications: 1 participant with INR between 3.1
and 3.9, 2 with INR > 4.0 on the day of the bleeding complication Furthermore, a figure
in the study publication provides data on INR values throughout the trial
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Derived by computer
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
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Hull 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Central independent adjudication com-
mittee interpreted events
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in analysis
Selective reporting (reporting bias) Low risk All data presented
Other bias Unclear risk Differences in initial treatment regimens
between groups
Hull 2009
Methods Multi-centre open-label randomised clinical trial
Participants 480 patients (240 allocated to LMWH and 240 to VKA treatment) with documented,
acute, proximal DVT
Age, < 60 years old/≥ 60 years old: LMWH 118/122, VKA 122/118
Gender, M/F: LMWH 139/101, VKA 138/102
Location: 22 centres across Canada
Interventions Participants received tinzaparin 175 IU/kg subcutaneously once daily for 12 weeks,
or tinzaparin for 5 days plus oral warfarin, commenced on day 1, INR-adjusted, and
continued for 12 weeks (’usual care’). Participants received 1 in-clinic injection, then
home treatment
Outcomes Primary efficacy outcome measure was occurrence of objectively documented, symp-
tomatic, recurrent VTE at 12 weeks and at 1 year. Other efficacy outcomes were death
rates at 12 weeks and 1 year; participants’ self-reported treatment satisfaction during the
treatment period; symptoms of PTS; and incidence of venous leg ulcers as reported by
participants. Primary safety outcome measure was occurrence of bleeding (all, major,
or minor) during the 12-week treatment period. Additional safety outcomes included
incidence of thrombocytopenia and of bone fracture
Blinded outcome assessment was provided by a central independent adjudication com-
mittee
Notes 3 months of randomised treatment and an additional 9 months of follow-up
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived treatment schedule
Allocation concealment (selection bias) Unclear risk Not clear
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Hull 2009 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes judged by a blinded central in-
dependent adjudication committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes presented. 3 participants lost
to follow-up at 12 months
Selective reporting (reporting bias) Low risk All outcomes presented
Other bias Unclear risk Differences in initial treatment regimens
between groups
Kakkar 2003
Methods Multi-centre randomised open-label parallel-group trial
Participants 297 patients (Group A: 98 allocated to 7 ± 2 days of unfractionated heparin followed by
a 3-month course of VKAs; Group B: 105 allocated to 7 ± 2 days of LMWH followed
by a 3-month course of VKAs; Group C: 94 allocated to 3 months of treatment with
LMWH, with DVT confirmed on venography
Age, years (range): Group A 61.2 (49.9 to 70.5), Group B 61.2 (44.4 to 69.5), Group
C 63.2 (45.1 to 70.8)
Gender, M, %: Group A 63, 64.3%; Group B 61, 58.1%; Group C 58, 61.7%
Location: 27 centres in 3 countries (Poland, Spain, UK)
Interventions Group A: First coumarin arm started with a 7 ± 2-day course of unfractionated heparin
followed by warfarin for 3 months (INR 2.0 to 3.0)
Group B: Second coumarin arm started with a 7 ± 2-day course of bemiparin 115 anti-
Xa IU/kg once daily, followed by warfarin for 3 months (INR 2.0 to 3.0)
Group C: Bemiparin arm received once-daily subcutaneous tinzaparin 115 anti-Xa IU/
kg of body weight for 10 days, followed by a fixed dose of 3500 anti-Xa IU for 90 days
Outcomes Recurrent VTE/
DVT: venography
PE: high-probability lung scan finding
Major bleeding: clinically overt and associated with a fall in Hb ≥ 2 g/dL, transfusion
of ≥ 2 units of blood, or intracranial or retroperitoneal bleeding
Mortality data were provided
Blinded outcome assessment was provided
Notes 3 months of randomised treatment and an additional 28 days of follow-up
Category II trial
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Kakkar 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information about generation of the
randomisation sequence
Allocation concealment (selection bias) Unclear risk No information about concealment of al-
location
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessment of outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-outs were only partially explained
Selective reporting (reporting bias) Low risk All planned outcomes reported
Other bias Low risk None observed
Kucher 2005
Methods Randomised controlled open-label single-institution treatment trial
Participants 40 patients (20 allocated to LMWH and 20 to VKA treatment) with PE confirmed
on high-probability ventilation-perfusion scanning, a positive contrast chest computed
tomogram, or a conventional pulmonary angiogram
Age, years, mean ± SD: LMWH 52 ± 17/VKA 51 ± 18
Gender, F: n, %: LMWH 15, 75%/VKA 14, 70%
Location: 1 centre in USA
Interventions Warfarin arm started with a course of enoxaparin (1 mg/kg) twice daily for ≥ 10 doses
overlapping 4 days with warfarin continued for 90 days. Enoxaparin arm started with a
course of 10 to 18 days at 1 mg/kg twice daily, followed by a 3-month course of once-
daily subcutaneous enoxaparin 1.5 mg/kg
10 participants were treated with thrombolysis because of right ventricular failure
Outcomes Recurrent VTE/DVT: filling defect on conventional venography or loss of vein com-
pressibility demonstrated on ultrasound
PE: high-probability lung scan finding, positive contrast chest computed tomogram, or
conventional pulmonary angiogram
Major bleeding: clinically overt and associated with a fall in Hb≥ 3 g/dL;or intracranial,
intraocular, retroperitoneal, or pericardial bleeding
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Kucher 2005 (Continued)
Mortality data were provided
Blinded outcome assessment was not provided
Notes 3 months of randomised treatment; thereafter treatment at the discretion of the treating
physician. No follow-up was provided after 3 months
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked computer randomisation
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Independent outcome collection not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No trial withdrawals
Selective reporting (reporting bias) Low risk Prospectively stated outcomes reported
Other bias Low risk None observed
Lopaciuk 1999
Methods Prospective open multi-centre randomised clinical trial
Participants 202 patients (101 allocated to LMWH and 101 to VKA treatment) with proximal DVT
confirmed on contrast phlebography. Evaluable data available for 98 LMWH and 95
VKA participants
Age, mean ± SD, years: LMWH 56.6 ± 16.2/VKA 57.8 ± 14.6
Gender, M/F: LMWH 45/53/VKA 49/46
Location: 11 centres in Poland
Interventions Acenocoumarol for 3 months (INR of 2.0 to 3.0) compared with a 3-month course of
once-daily subcutaneous nadroparin (85 anti-Xa units per kilogram)
Both treatment arms startedwith a 10-day course of twice-daily subcutaneous nadroparin
85 anti-Xa units per kilogram
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Lopaciuk 1999 (Continued)
Outcomes Recurrent VTE/DVT: new constant intraluminal filling defect compared with baseline
venography
PE: new segmental or greater perfusion defect on lung scan or positive pulmonary
angiogram
Major bleeding: overt bleeding associated with a fall in Hb ≥ 2 g/dL with need for
transfusion of ≥ 2 units of packed red cells or intracranial or retroperitoneal bleeding
Mortality from all causes
Blinded outcome assessment was not provided
Notes 3 months of randomised treatment and an additional 9 months of follow-up
21 participants (22%) used acenocoumarol for an additional 3 months, 5 (5%) for 9
months, and 15 (16%) for 1 year. In the nadroparin group, 7 participants (7%) prolonged
treatment to 4 to 5 months, and 1 participant to 9 months
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinded outcome assessment not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals accounted for
Selective reporting (reporting bias) Low risk Prospectively stated outcomes reported
Other bias Unclear risk 3 fatal peripheral or cardiovascular events in
the acenocoumarol group are not discussed.
Follow-up treatments after planned 3-
month outcomes differed between groups
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Lopez 2001
Methods Prospective open single-centre randomised clinical trial
Participants 158 patients (81 allocated to LMWH and 77 to VKA treatment) with a first DVT
episode in this leg confirmed on duplex scan examination
Age, mean (95% CI), years: LMWH 65 (62 to 69)/VKA 66 (63 to 70)
Gender, M/F: LMWH 31/50/VKA 38/39
Location: 1 centre in Spain
Interventions Acenocoumarol for 3 or 6 months (INR 2.0 to 3.0) compared with subcutaneous
nadroparin adjusted to body weight 2 times daily (1025 anti-Xa IU/10 kg). Both treat-
ment arms started with a course of≥ 5 days of treatment with subcutaneous nadroparin
twice daily (1025 anti-Xa IU/10 kg)
Outcomes Recurrent VTE/DVT: appearance of thrombosis in a previously unaffected venous seg-
ment of the ipsilateral or contralateral leg
PE: constant intraluminal filling defect on spiral computed tomography or conventional
angiography
Major bleeding: overt bleeding associated with a decrease ≥ 2 g/dL in Hb level; require-
ment for blood transfusion of≥ 2 units; intracranial or retroperitoneal bleeding; or need
for permanent discontinuation of treatment. All other episodes of bleeding were defined
as minor
Notes 3 to 6 months of randomised treatment and an additional 6 to 9 months of follow-up.
44 participants in the acenocoumarol group and 34 in the nadroparin group were treated
for 6 months. The remainder were treated for 3 months
Control INR values were less than 2.0 in 22.8%, between 2 and 3 in 67.8%, and above
3 in 9.4% of cases
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence not re-
ported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blind outcomes collected by independent
panel of physicians
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals explained
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Lopez 2001 (Continued)
Selective reporting (reporting bias) Low risk All prospectively started outcomes reported
Other bias Low risk None observed
Massicotte 2003
Methods Multi-centre open-label randomised clinical trial
Participants 78 patients (all children) (37 allocated to reviparin and 41 to unfractionated heparin
plus anticoagulant) with DVT confirmed on venography or compression ultrasound, or
PE confirmed on ventilation-perfusion scan or pulmonary angiogram
Age, mean ± SD, years: LMWH 9.4 ± 6.6/VKA 8.7 ± 5.9
Gender, M/F: LMWH 17/20/VKA 19/22
Location: 37 centres in 6 countries (Australia, Canada, Germany, The Netherlands, UK,
USA)
Interventions Interventions started within 48 hours of randomisation
3 months of 100 IU/kg reviparin sodium (Knoll, Germany) compared with 3 months
of UFH followed by oral anticoagulants
Outcomes Recurrent VTE during 3 months of treatment and subsequent 3-month follow-up or
death due to DVT
Other outcomes:
- Safety outcomes
- Major bleeding defined as clinically significant overt bleeding requiring immediate
transfusion of red blood cells, or any retroperitoneal, intracranial, or intra-articular bleed-
ing
- Minor bleeding defined as bruising, oozing around intravenous sites and surgical
wounds, small amount of blood from suctioning of endotracheal tubes, small amounts
of blood in urine or stool, and minor nosebleeds
Notes 3 months of randomised treatment and an additional 3 months of follow-up
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived protocol
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
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Massicotte 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent and blinded central adju-
dication committee assessed all outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 78 participants, 66 completed the trial,
17 withdrew, and 5 died
Selective reporting (reporting bias) Low risk All prospectively stated outcomes were pre-
sented
Other bias Unclear risk Differences in initial treatment regimens
between groups
Perez-de-Llano 2010
Methods Randomised multi-centre open-label trial
Participants 102 patients (52 allocated to LMWH monotherapy and 50 to LMWH followed by
chronic VKA treatment) with objectively confirmed PE (perfusion lung scan or chest
computed tomogram)
Age, year (range): LMWH 72.4 (25 to 93)/VKA 72.1 (24 to 91)
Gender, male, %: LMWH 25, 50%/VKA 28, 53.9%
Location: 4 centres in Spain
Interventions Participants received tinzaparin 175 IU/kg subcutaneously once daily for 6 months, or
tinzaparin plus oral acenocoumarol, commenced within 48 hours of the first dose of
tinzaparin, INR-adjusted, and continued for 6 months. In this latter group, tinzaparin
was continued until INR was > 2 on 2 consecutive days
Outcomes Symptomatic, recurrent VTE at 1 month, 3 months, and 6 months (on compression
ultrasonography or helical computed tomography)
Composite of major and minor clinically relevant bleeding during treatment. Bleeding
was defined as major if it was clinically associated with a decrease in Hb levels≥ 2 g/dL,
required a transfusion of≥ 2 units of red blood cells, or was intracranial or retroperitoneal
Other adverse reactions were also reported
Blinded outcome assessment was not provided
Notes Category II trial
INR values after discharge were 51.7% of measurements within therapeutic range, 41.
5% below, and 6.8% above
LEO Pharma provided indemnity and grants to support the study, and 2 study authors
reported lecturing or working for LEO Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
40Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Perez-de-Llano 2010 (Continued)
Random sequence generation (selection
bias)
Low risk “We stratified randomization through a
central computer-generated list”
Allocation concealment (selection bias) Unclear risk Randomisation through a central com-
puter-generated list - no other information
regarding allocation concealment provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Eight patients did not complete the 6-
month protocol successfully: five (9.7%)
randomized to tinzaparin (metastatic can-
cer, allergy to tinzaparin, vein thrombosis
and for two patients the reason was un-
known) and three (6%) to VKA (metastatic
cancer, inability to reach therapeutic INR
and for one patents the reason was un-
known)”
All withdrawals and reasons for withdrawal
reported
Selective reporting (reporting bias) Low risk Prospectively stated outcomes reported
Other bias Low risk None observed
Pini 1994
Methods Prospective open single-centre randomised clinical trial
Participants 187 patients (93 allocated to LMWH and 94 to VKA treatment) with first or second
episode of symptomatic DVT confirmed on strain-gauge plethysmography combined
with a positive D-dimer latex test most often confirmed with contrast venography
Age, years, mean: LMWH 65.4/VKA 65.0
Gender, M/F: LMWH 47/46/VKA 54/40
Location: 1 centre in Italy
Interventions 3 months of conventional treatment with warfarin (INR 2.0 to 3.5), compared with
a 3-month course of enoxaparin 4000 anti-Xa units once daily. All participants were
initially treated with a 10-day course of subcutaneous unfractionated heparin adjusted
to an APTT of about 1.3 to 1.9 times the participant’s basal value
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Pini 1994 (Continued)
Outcomes Recurrent VTE/DVT: new intraluminal filling defect in the deep veins by repeated
venography or, if marked reduction of strain-gauge plethysmography, coupled with a
positive D-dimer test that followed a negative one
PE: defined by single or multiple segmental defects at perfusion scan with no abnormal-
ities on chest radiograph in that area, on positive pulmonary angiogram, or at autopsy
Major bleeding: clinically overt bleeding associated with a fall in haemoglobin of 2 g/
dL leading to a blood transfusion, or intracranial or retroperitoneal bleeding. All other
episodes were defined as minor
Mortality from all causes
Blinded outcome assessment was provided by an independent panel of physicians who
were unaware of treatment allocation
Notes 3 months of randomised treatment and an additional 9 months of follow-up
Anticoagulation was graded as good in 38% of participants (≥ 67% of INR values within
therapeutic range), intermediate in 43% (34% to 66% of values in the therapeutic range)
, and poor in 19% of cases (< 34% of values in the therapeutic range)
Category I trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-derived generation
Allocation concealment (selection bias) Unclear risk Allocation concealment not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Final adjudication of outcome measures
conducted by an independent panel of
physicians, 1 of whom was not involved in
the trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participant exclusions explained and no en-
rolled participants dropped out
Selective reporting (reporting bias) Low risk All 3 outcomes reported (recurrent VTE,
PE, and bleeding); deaths also reported
Other bias Low risk None observed
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Romera 2009
Methods Open-label prospective randomised clinical trial
Participants 241 patients (119 allocated to LMWH and 122 to VKA treatment) with an episode of
symptomatic DVT confirmed on duplex ultrasonography
Age, mean ± SD, years: LMWH 58.9 ± 17.6/VKA: 61.3 ± 16.2
Gender, male, %: LMWH 64, 53.8%/VKA: 70, 57.4%
Location: 2 centres in Spain
Interventions Warfarin arm started with a course of tinzaparin 175 anti-Xa IU/kg of body weight
followed by warfarin for 6 months (INR 2.0 to 3.0). Tinzaparin group received once-
daily subcutaneous tinzaparin 175 anti-Xa IU/kgof bodyweight, continued for 6months
Outcomes Recurrent VTE/
DVT: previously compressible proximal vein segment no longer compressible on ultra-
sonography
PE: high-probability lung scan with clinical suspicion, abnormal perfusion scan with
documented new DVT or spiral computed tomography showing thrombus in the pul-
monary arteries
Major bleeding: clinically overt bleeding associated with a fall in Hb≥ 2 g/dL leading to
blood transfusion of ≥ 2 units; or intracranial or retroperitoneal bleeding, or bleeding
in a major joint
Mortality of all causes
Blinded outcome assessment was provided
Notes 6 months of randomised treatment and an additional 6 months of follow-up
One note was made of the adequateness of anticoagulation during VKA treatment
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label, not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independently collected outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data presented
Selective reporting (reporting bias) Low risk All prospectively stated outcomes reported
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Romera 2009 (Continued)
Other bias Low risk None observed
Veiga 2000
Methods Prospective open single-centre randomised clinical trial
Participants 100 patients (50 allocated to LMWH and 50 to VKA treatment) ≥ 75 years of age with
a symptomatic proximal DVT confirmed on phlebography
Age, mean, years: LMWH 80.9/VKA 79.6
Gender, M/F: LMWH 17/33/VKA 24/26
Location: 1 centre in Spain
Interventions Acenocoumarol for 3 or 6 months (INR 2.0 to 3.0) compared with once-daily subcu-
taneous enoxaparin 40 mg (4000 IU Factor Xa inhibitor). Both treatment arms started
with a course of ≥ 10 days of intravenous unfractionated heparin. Starting with a bolus
of 5000 IU and followed by 4000 IU administered every 4 hours, with a target APTT
of 1.5 to 2.0 times baseline APTT
Outcomes Recurrent VTE/DVT: new filling defect observed on phlebography
PE: pulmonary scintigraphy and/or pulmonary arteriography. Necropsy was performed
when necessary
Major bleeding: overt bleeding and associated with a decrease in Hb of ≥ 2 g/dLl
requiring a blood transfusion; retroperitoneal, intracranial, or intra-articular, or leading
to death. All other episodes of bleeding were defined as minor
Notes 3 to 6 months of randomised treatment and an additional 6 to 9 months of follow-up.
7 participants in the acenocoumarol group and 5 in the enoxaparin group were treated
for 6 months. The remainder were treated for 3 months
Therapeutic compliance was graded as good in 15 (30%) participants (within desired
INR range on more than 75% of occasions), acceptable in 28 (56%) participants (within
INR target range on 50% to 75% of occasions), and poor in 7 (14%) participants (< 50%
of occasions within the target range). In the enoxaparin group, 4 participants reported
slight irregularities; in 5 others, the number of vials returned did not correspond exactly
with doses needed for that time period
Category II trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Closed envelopes used but no further in-
formation provided
Allocation concealment (selection bias) Low risk Closed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial - not blind: LMWH ad-
ministered to hospitalised participants vs
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Veiga 2000 (Continued)
acenocoumarol outpatient participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes collected by independent spe-
cialists
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk All prospectively stated outcomes were ac-
counted for
Other bias Low risk None observed
APTT: activated partial thromboplastin time
CI: confidence interval
DVT: deep venous thrombosis
Hb: haemoglobin
INR: international normalised ratio
IU: international units
LMWH: low-molecular-weight heparin
PE: pulmonary embolism
PTS: post-thrombotic syndrome
SD: standard deviation
UFH: unfractionated heparin
VKA; vitamin K antagonist
VTE: venous thromboembolism
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ghirarduzzi 2009 Composite endpoint trial
Hull 2001 Subjective participant-reported outcomes
Hull 2001a Subjective participant-reported outcomes
Vorobyeva 2009 Non-randomised trial
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D A T A A N D A N A L Y S E S
Comparison 1. LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 16 3299 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.60, 1.15]
2 Incidence of major bleeding 16 3299 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.51 [0.32, 0.80]
3 Mortality 16 3299 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.75, 1.56]
Comparison 2. LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 12 3021 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.57, 1.11]
2 Incidence of major bleeding 12 3021 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.33, 0.88]
3 Mortality 12 3021 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.10 [0.75, 1.60]
Comparison 3. LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 3 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.70 [0.91, 35.60]
2 Incidence of major bleeding 3 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.23 [0.03, 1.78]
3 Mortality 3 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.39 [0.51, 57.36]
Comparison 4. LMWH versus VKA during allocated treatment (category I trials) in participants with VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 7 1872 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.80 [0.54, 1.18]
2 Incidence of major bleeding 7 1872 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.36, 1.07]
3 Mortality 7 1872 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.61, 1.41]
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Comparison 5. Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 2 292 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.95 [0.74, 5.19]
2 Incidence of major bleeding 2 292 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.20, 5.12]
3 Mortality 2 292 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.89 [0.29, 2.68]
Comparison 6. Category I trials and initial treatment not the same in both groups (unfractionated heparin
compared with LMWH)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 5 1580 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.44, 1.03]
2 Incidence of major bleeding 5 1580 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.33, 1.04]
3 Mortality 5 1580 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.93 [0.59, 1.46]
Comparison 7. LMWH versus VKA during additional follow-up (category I and II trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 10 2592 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.77, 1.64]
2 Incidence of major bleeding 9 2112 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mortality 10 2592 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.71, 1.40]
Comparison 8. LMWH versus VKA during additional nine months of follow-up (category I trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 5 1691 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.81, 1.98]
2 Incidence of major bleeding 4 1211 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mortality 5 1691 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.72, 1.55]
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Comparison 9. LMWH versus VKA for total period of 12 months of follow-up (category I and II trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 10 2592 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.88 [0.67, 1.15]
2 Incidence of major bleeding 9 2112 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.56 [0.33, 0.95]
3 Mortality 10 2592 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.09 [0.84, 1.43]
Comparison 10. LMWH versus VKA for total period of 12 months of follow-up (category I trials)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of recurrent VTE 5 1691 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.70, 1.30]
2 Incidence of major bleeding 4 1211 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.72 [0.39, 1.32]
3 Mortality 5 1691 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.78, 1.42]
Analysis 1.1. Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with VTE, Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 3/40 0/20 1.8 % 4.72 [ 0.41, 54.32 ]
Das 1996 5/50 2/55 4.5 % 2.75 [ 0.60, 12.69 ]
Daskalopoulos 2005 2/50 3/52 3.3 % 0.69 [ 0.11, 4.11 ]
Gonzalez 1999 8/93 19/92 16.0 % 0.38 [ 0.17, 0.86 ]
Hamann 1998 3/100 2/100 3.4 % 1.50 [ 0.26, 8.84 ]
Hull 2007 18/369 21/368 25.5 % 0.85 [ 0.45, 1.62 ]
Hull 2009 8/240 8/240 10.7 % 1.00 [ 0.37, 2.71 ]
Kakkar 2003 3/103 5/221 4.7 % 1.31 [ 0.29, 5.89 ]
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Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Kucher 2005 1/20 0/20 0.7 % 7.39 [ 0.15, 372.38 ]
Lopaciuk 1999 3/101 7/101 6.6 % 0.43 [ 0.12, 1.54 ]
Lopez 2001 0/81 3/77 2.0 % 0.13 [ 0.01, 1.22 ]
Massicotte 2003 2/36 4/40 3.8 % 0.55 [ 0.10, 2.87 ]
Perez-de-Llano 2010 1/52 0/50 0.7 % 7.11 [ 0.14, 358.60 ]
Pini 1994 6/93 4/94 6.5 % 1.54 [ 0.43, 5.49 ]
Romera 2009 5/119 7/122 7.9 % 0.72 [ 0.23, 2.31 ]
Veiga 2000 2/50 1/50 2.0 % 1.97 [ 0.20, 19.43 ]
Total (95% CI) 1597 1702 100.0 % 0.83 [ 0.60, 1.15 ]
Total events: 70 (LMWH), 86 (VKA)
Heterogeneity: Chi2 = 16.53, df = 15 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with VTE, Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 0/40 2/20 2.4 % 0.05 [ 0.00, 0.92 ]
Das 1996 0/50 0/55 Not estimable
Daskalopoulos 2005 2/50 4/52 7.9 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 2/92 4.1 % 0.50 [ 0.05, 4.91 ]
Hamann 1998 0/100 2/100 2.8 % 0.13 [ 0.01, 2.16 ]
Hull 2007 12/369 17/368 38.7 % 0.70 [ 0.33, 1.46 ]
Hull 2009 1/240 3/240 5.5 % 0.37 [ 0.05, 2.61 ]
Kakkar 2003 1/103 1/221 2.4 % 2.32 [ 0.12, 45.75 ]
Kucher 2005 0/20 0/20 Not estimable
Lopaciuk 1999 1/101 1/101 2.8 % 1.00 [ 0.06, 16.10 ]
Lopez 2001 0/81 4/77 5.4 % 0.12 [ 0.02, 0.89 ]
Massicotte 2003 2/36 5/40 8.9 % 0.44 [ 0.09, 2.07 ]
Perez-de-Llano 2010 1/52 1/50 2.7 % 0.96 [ 0.06, 15.59 ]
Pini 1994 3/93 3/94 8.1 % 1.01 [ 0.20, 5.12 ]
Romera 2009 1/119 3/122 5.5 % 0.37 [ 0.05, 2.68 ]
Veiga 2000 0/50 2/50 2.7 % 0.13 [ 0.01, 2.15 ]
Total (95% CI) 1597 1702 100.0 % 0.51 [ 0.32, 0.80 ]
Total events: 25 (LMWH), 50 (VKA)
Heterogeneity: Chi2 = 9.25, df = 13 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with VTE, Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 1 LMWH versus VKA during allocated treatment (category I and II trials) in participants with VTE
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 2/40 0/20 1.5 % 4.60 [ 0.24, 89.21 ]
Das 1996 1/50 3/55 3.4 % 0.39 [ 0.05, 2.88 ]
Daskalopoulos 2005 2/50 4/52 5.0 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 0/92 0.9 % 7.31 [ 0.15, 368.42 ]
Hamann 1998 1/100 1/100 1.7 % 1.00 [ 0.06, 16.10 ]
Hull 2007 25/369 24/368 40.1 % 1.04 [ 0.58, 1.86 ]
Hull 2009 9/240 9/240 15.2 % 1.00 [ 0.39, 2.56 ]
Kakkar 2003 1/103 4/221 3.7 % 0.58 [ 0.09, 3.83 ]
Kucher 2005 0/20 0/20 Not estimable
Lopaciuk 1999 3/101 2/101 4.3 % 1.50 [ 0.26, 8.84 ]
Lopez 2001 7/81 3/77 8.2 % 2.22 [ 0.62, 7.95 ]
Massicotte 2003 1/36 4/40 4.1 % 0.31 [ 0.05, 1.91 ]
Perez-de-Llano 2010 1/52 0/50 0.9 % 7.11 [ 0.14, 358.60 ]
Pini 1994 5/93 4/94 7.5 % 1.28 [ 0.34, 4.85 ]
Romera 2009 0/119 0/122 Not estimable
Veiga 2000 3/50 1/50 3.4 % 2.80 [ 0.38, 20.52 ]
Total (95% CI) 1597 1702 100.0 % 1.08 [ 0.75, 1.56 ]
Total events: 62 (LMWH), 59 (VKA)
Heterogeneity: Chi2 = 9.05, df = 13 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with DVT, Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 5/50 2/55 4.9 % 2.75 [ 0.60, 12.69 ]
Daskalopoulos 2005 2/50 3/52 3.6 % 0.69 [ 0.11, 4.11 ]
Gonzalez 1999 8/93 19/92 17.2 % 0.38 [ 0.17, 0.86 ]
Hamann 1998 3/100 2/100 3.6 % 1.50 [ 0.26, 8.84 ]
Hull 2007 18/369 21/368 27.4 % 0.85 [ 0.45, 1.62 ]
Hull 2009 8/240 8/240 11.5 % 1.00 [ 0.37, 2.71 ]
Kakkar 2003 3/103 5/221 5.0 % 1.31 [ 0.29, 5.89 ]
Lopaciuk 1999 3/101 7/101 7.1 % 0.43 [ 0.12, 1.54 ]
Lopez 2001 0/81 3/77 2.2 % 0.13 [ 0.01, 1.22 ]
Pini 1994 6/93 4/94 7.0 % 1.54 [ 0.43, 5.49 ]
Romera 2009 5/119 7/122 8.5 % 0.72 [ 0.23, 2.31 ]
Veiga 2000 2/50 1/50 2.2 % 1.97 [ 0.20, 19.43 ]
Total (95% CI) 1449 1572 100.0 % 0.79 [ 0.57, 1.11 ]
Total events: 63 (LMWH), 82 (VKA)
Heterogeneity: Chi2 = 11.92, df = 11 (P = 0.37); I2 =8%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with DVT, Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 0/50 0/55 Not estimable
Daskalopoulos 2005 2/50 4/52 9.2 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 2/92 4.8 % 0.50 [ 0.05, 4.91 ]
Hamann 1998 0/100 2/100 3.2 % 0.13 [ 0.01, 2.16 ]
Hull 2007 12/369 17/368 45.0 % 0.70 [ 0.33, 1.46 ]
Hull 2009 1/240 3/240 6.4 % 0.37 [ 0.05, 2.61 ]
Kakkar 2003 1/103 1/221 2.8 % 2.32 [ 0.12, 45.75 ]
Lopaciuk 1999 1/101 1/101 3.2 % 1.00 [ 0.06, 16.10 ]
Lopez 2001 0/81 4/77 6.3 % 0.12 [ 0.02, 0.89 ]
Pini 1994 3/93 3/94 9.4 % 1.01 [ 0.20, 5.12 ]
Romera 2009 1/119 3/122 6.4 % 0.37 [ 0.05, 2.68 ]
Veiga 2000 0/50 2/50 3.2 % 0.13 [ 0.01, 2.15 ]
Total (95% CI) 1449 1572 100.0 % 0.54 [ 0.33, 0.88 ]
Total events: 22 (LMWH), 42 (VKA)
Heterogeneity: Chi2 = 6.51, df = 10 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with DVT, Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 2 LMWH versus VKA during allocated treatment (category I and II trials) in participants with DVT
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 1/50 3/55 3.6 % 0.39 [ 0.05, 2.88 ]
Daskalopoulos 2005 2/50 4/52 5.3 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 0/92 0.9 % 7.31 [ 0.15, 368.42 ]
Hamann 1998 1/100 1/100 1.9 % 1.00 [ 0.06, 16.10 ]
Hull 2007 25/369 24/368 42.9 % 1.04 [ 0.58, 1.86 ]
Hull 2009 9/240 9/240 16.3 % 1.00 [ 0.39, 2.56 ]
Kakkar 2003 1/103 4/221 4.0 % 0.58 [ 0.09, 3.83 ]
Lopaciuk 1999 3/101 2/101 4.6 % 1.50 [ 0.26, 8.84 ]
Lopez 2001 7/81 3/77 8.8 % 2.22 [ 0.62, 7.95 ]
Pini 1994 5/93 4/94 8.1 % 1.28 [ 0.34, 4.85 ]
Romera 2009 0/119 0/122 Not estimable
Veiga 2000 3/50 1/50 3.6 % 2.80 [ 0.38, 20.52 ]
Total (95% CI) 1449 1572 100.0 % 1.10 [ 0.75, 1.60 ]
Total events: 58 (LMWH), 55 (VKA)
Heterogeneity: Chi2 = 5.43, df = 10 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with PE, Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 3/40 0/20 56.3 % 4.72 [ 0.41, 54.32 ]
Kucher 2005 1/20 0/20 21.9 % 7.39 [ 0.15, 372.38 ]
Perez-de-Llano 2010 1/52 0/50 21.8 % 7.11 [ 0.14, 358.60 ]
Total (95% CI) 112 90 100.0 % 5.70 [ 0.91, 35.60 ]
Total events: 5 (LMWH), 0 (VKA)
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with PE, Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 0/40 2/20 46.9 % 0.05 [ 0.00, 0.92 ]
Kucher 2005 0/20 0/20 Not estimable
Perez-de-Llano 2010 1/52 1/50 53.1 % 0.96 [ 0.06, 15.59 ]
Total (95% CI) 112 90 100.0 % 0.23 [ 0.03, 1.78 ]
Total events: 1 (LMWH), 3 (VKA)
Heterogeneity: Chi2 = 2.11, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 LMWH versus VKA during allocated treatment (category I and II trials) in
participants with PE, Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 3 LMWH versus VKA during allocated treatment (category I and II trials) in participants with PE
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Beckman 2003 2/40 0/20 63.6 % 4.60 [ 0.24, 89.21 ]
Kucher 2005 0/20 0/20 Not estimable
Perez-de-Llano 2010 1/52 0/50 36.4 % 7.11 [ 0.14, 358.60 ]
Total (95% CI) 112 90 100.0 % 5.39 [ 0.51, 57.36 ]
Total events: 3 (LMWH), 0 (VKA)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in
participants with VTE, Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 5/50 2/55 6.4 % 2.75 [ 0.60, 12.69 ]
Daskalopoulos 2005 2/50 3/52 4.7 % 0.69 [ 0.11, 4.11 ]
Gonzalez 1999 8/93 19/92 22.7 % 0.38 [ 0.17, 0.86 ]
Hull 2007 18/369 21/368 36.2 % 0.85 [ 0.45, 1.62 ]
Hull 2009 8/240 8/240 15.2 % 1.00 [ 0.37, 2.71 ]
Massicotte 2003 2/36 4/40 5.5 % 0.55 [ 0.10, 2.87 ]
Pini 1994 6/93 4/94 9.3 % 1.54 [ 0.43, 5.49 ]
Total (95% CI) 931 941 100.0 % 0.80 [ 0.54, 1.18 ]
Total events: 49 (LMWH), 61 (VKA)
Heterogeneity: Chi2 = 7.15, df = 6 (P = 0.31); I2 =16%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in
participants with VTE, Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 0/50 0/55 Not estimable
Daskalopoulos 2005 2/50 4/52 10.8 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 2/92 5.6 % 0.50 [ 0.05, 4.91 ]
Hull 2007 12/369 17/368 52.8 % 0.70 [ 0.33, 1.46 ]
Hull 2009 1/240 3/240 7.5 % 0.37 [ 0.05, 2.61 ]
Massicotte 2003 2/36 5/40 12.2 % 0.44 [ 0.09, 2.07 ]
Pini 1994 3/93 3/94 11.1 % 1.01 [ 0.20, 5.12 ]
Total (95% CI) 931 941 100.0 % 0.62 [ 0.36, 1.07 ]
Total events: 21 (LMWH), 34 (VKA)
Heterogeneity: Chi2 = 0.99, df = 5 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 LMWH versus VKA during allocated treatment (category I trials) in
participants with VTE, Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 4 LMWH versus VKA during allocated treatment (category I trials) in participants with VTE
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 1/50 3/55 4.5 % 0.39 [ 0.05, 2.88 ]
Daskalopoulos 2005 2/50 4/52 6.5 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 0/92 1.1 % 7.31 [ 0.15, 368.42 ]
Hull 2007 25/369 24/368 52.6 % 1.04 [ 0.58, 1.86 ]
Hull 2009 9/240 9/240 19.9 % 1.00 [ 0.39, 2.56 ]
Massicotte 2003 1/36 4/40 5.4 % 0.31 [ 0.05, 1.91 ]
Pini 1994 5/93 4/94 9.9 % 1.28 [ 0.34, 4.85 ]
Total (95% CI) 931 941 100.0 % 0.92 [ 0.61, 1.41 ]
Total events: 44 (LMWH), 48 (VKA)
Heterogeneity: Chi2 = 4.05, df = 6 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated
heparin or LMWH), Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 5/50 2/55 40.9 % 2.75 [ 0.60, 12.69 ]
Pini 1994 6/93 4/94 59.1 % 1.54 [ 0.43, 5.49 ]
Total (95% CI) 143 149 100.0 % 1.95 [ 0.74, 5.19 ]
Total events: 11 (LMWH), 6 (VKA)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated
heparin or LMWH), Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 0/50 0/55 Not estimable
Pini 1994 3/93 3/94 100.0 % 1.01 [ 0.20, 5.12 ]
Total (95% CI) 143 149 100.0 % 1.01 [ 0.20, 5.12 ]
Total events: 3 (LMWH), 3 (VKA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Category I trials and the same initial treatment in both groups (unfractionated
heparin or LMWH), Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 5 Category I trials and the same initial treatment in both groups (unfractionated heparin or LMWH)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Das 1996 1/50 3/55 31.0 % 0.39 [ 0.05, 2.88 ]
Pini 1994 5/93 4/94 69.0 % 1.28 [ 0.34, 4.85 ]
Total (95% CI) 143 149 100.0 % 0.89 [ 0.29, 2.68 ]
Total events: 6 (LMWH), 7 (VKA)
Heterogeneity: Chi2 = 0.93, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Category I trials and initial treatment not the same in both groups
(unfractionated heparin compared with LMWH), Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 3/52 5.6 % 0.69 [ 0.11, 4.11 ]
Gonzalez 1999 8/93 19/92 26.9 % 0.38 [ 0.17, 0.86 ]
Hull 2007 18/369 21/368 43.0 % 0.85 [ 0.45, 1.62 ]
Hull 2009 8/240 8/240 18.0 % 1.00 [ 0.37, 2.71 ]
Massicotte 2003 2/36 4/40 6.5 % 0.55 [ 0.10, 2.87 ]
Total (95% CI) 788 792 100.0 % 0.68 [ 0.44, 1.03 ]
Total events: 38 (LMWH), 55 (VKA)
Heterogeneity: Chi2 = 3.01, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Category I trials and initial treatment not the same in both groups
(unfractionated heparin compared with LMWH), Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 4/52 12.1 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 2/92 6.3 % 0.50 [ 0.05, 4.91 ]
Hull 2007 12/369 17/368 59.4 % 0.70 [ 0.33, 1.46 ]
Hull 2009 1/240 3/240 8.5 % 0.37 [ 0.05, 2.61 ]
Massicotte 2003 2/36 5/40 13.7 % 0.44 [ 0.09, 2.07 ]
Total (95% CI) 788 792 100.0 % 0.59 [ 0.33, 1.04 ]
Total events: 18 (LMWH), 31 (VKA)
Heterogeneity: Chi2 = 0.60, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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(unfractionated heparin compared with LMWH), Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 6 Category I trials and initial treatment not the same in both groups (unfractionated heparin compared with LMWH)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 4/52 7.6 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 0/92 1.3 % 7.31 [ 0.15, 368.42 ]
Hull 2007 25/369 24/368 61.4 % 1.04 [ 0.58, 1.86 ]
Hull 2009 9/240 9/240 23.3 % 1.00 [ 0.39, 2.56 ]
Massicotte 2003 1/36 4/40 6.3 % 0.31 [ 0.05, 1.91 ]
Total (95% CI) 788 792 100.0 % 0.93 [ 0.59, 1.46 ]
Total events: 38 (LMWH), 41 (VKA)
Heterogeneity: Chi2 = 3.12, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 7 LMWH versus VKA during additional follow-up (category I and II trials)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 0/50 2/52 1.9 % 0.14 [ 0.01, 2.24 ]
Gonzalez 1999 3/93 3/92 5.5 % 0.99 [ 0.20, 5.01 ]
Hamann 1998 0/100 0/100 Not estimable
Hull 2007 15/369 15/368 27.1 % 1.00 [ 0.48, 2.07 ]
Hull 2009 17/240 12/240 25.7 % 1.44 [ 0.68, 3.05 ]
Lopaciuk 1999 5/101 2/101 6.4 % 2.42 [ 0.54, 10.89 ]
Lopez 2001 2/81 4/77 5.5 % 0.48 [ 0.09, 2.42 ]
Pini 1994 10/93 4/94 12.3 % 2.54 [ 0.86, 7.53 ]
Romera 2009 1/119 6/122 6.4 % 0.24 [ 0.05, 1.06 ]
Veiga 2000 6/50 5/50 9.3 % 1.22 [ 0.35, 4.26 ]
Total (95% CI) 1296 1296 100.0 % 1.12 [ 0.77, 1.64 ]
Total events: 59 (LMWH), 53 (VKA)
Heterogeneity: Chi2 = 11.12, df = 8 (P = 0.20); I2 =28%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
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Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 7 LMWH versus VKA during additional follow-up (category I and II trials)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 0/50 0/52 Not estimable
Gonzalez 1999 0/93 0/92 Not estimable
Hamann 1998 0/100 0/100 Not estimable
Hull 2007 0/369 0/368 Not estimable
Lopaciuk 1999 0/101 0/101 Not estimable
Lopez 2001 0/81 0/77 Not estimable
Pini 1994 0/93 0/94 Not estimable
Romera 2009 0/119 0/122 Not estimable
Veiga 2000 0/50 0/50 Not estimable
Total (95% CI) 1056 1056 Not estimable
Total events: 0 (LMWH), 0 (VKA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 7 LMWH versus VKA during additional follow-up (category I and II trials)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 5/52 4.9 % 0.42 [ 0.09, 1.93 ]
Gonzalez 1999 4/93 3/92 5.1 % 1.33 [ 0.29, 5.99 ]
Hamann 1998 0/100 0/100 Not estimable
Hull 2007 35/369 35/368 47.6 % 1.00 [ 0.61, 1.63 ]
Hull 2009 13/240 12/240 17.8 % 1.09 [ 0.49, 2.43 ]
Lopaciuk 1999 1/101 2/101 2.2 % 0.51 [ 0.05, 4.96 ]
Lopez 2001 2/81 3/77 3.7 % 0.63 [ 0.11, 3.72 ]
Pini 1994 6/93 4/94 7.1 % 1.54 [ 0.43, 5.49 ]
Romera 2009 2/119 2/122 3.0 % 1.03 [ 0.14, 7.37 ]
Veiga 2000 7/50 6/50 8.6 % 1.19 [ 0.37, 3.80 ]
Total (95% CI) 1296 1296 100.0 % 1.00 [ 0.71, 1.40 ]
Total events: 72 (LMWH), 72 (VKA)
Heterogeneity: Chi2 = 2.55, df = 8 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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trials), Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 8 LMWH versus VKA during additional nine months of follow-up (category I trials)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 0/50 2/52 2.6 % 0.14 [ 0.01, 2.24 ]
Gonzalez 1999 3/93 3/92 7.6 % 0.99 [ 0.20, 5.01 ]
Hull 2007 15/369 15/368 37.4 % 1.00 [ 0.48, 2.07 ]
Hull 2009 17/240 12/240 35.5 % 1.44 [ 0.68, 3.05 ]
Pini 1994 10/93 4/94 16.9 % 2.54 [ 0.86, 7.53 ]
Total (95% CI) 845 846 100.0 % 1.26 [ 0.81, 1.98 ]
Total events: 45 (LMWH), 36 (VKA)
Heterogeneity: Chi2 = 4.63, df = 4 (P = 0.33); I2 =14%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 LMWH versus VKA during additional nine months of follow-up (category I
trials), Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 8 LMWH versus VKA during additional nine months of follow-up (category I trials)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 0/50 0/52 Not estimable
Gonzalez 1999 0/93 0/92 Not estimable
Hull 2007 0/369 0/368 Not estimable
Pini 1994 0/93 0/94 Not estimable
Total (95% CI) 605 606 Not estimable
Total events: 0 (LMWH), 0 (VKA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours LMWH Favours VKA
70Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
(Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.3. Comparison 8 LMWH versus VKA during additional nine months of follow-up (category I
trials), Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 8 LMWH versus VKA during additional nine months of follow-up (category I trials)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 0/50 1/52 1.0 % 0.14 [ 0.00, 7.09 ]
Gonzalez 1999 4/93 3/92 6.5 % 1.33 [ 0.29, 5.99 ]
Hull 2007 35/369 35/368 60.7 % 1.00 [ 0.61, 1.63 ]
Hull 2009 13/240 12/240 22.7 % 1.09 [ 0.49, 2.43 ]
Pini 1994 6/93 4/94 9.1 % 1.54 [ 0.43, 5.49 ]
Total (95% CI) 845 846 100.0 % 1.06 [ 0.72, 1.55 ]
Total events: 58 (LMWH), 55 (VKA)
Heterogeneity: Chi2 = 1.50, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 LMWH versus VKA for total period of 12 months of follow-up (category I and II
trials), Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 9 LMWH versus VKA for total period of 12 months of follow-up (category I and II trials)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 5/52 3.0 % 0.42 [ 0.09, 1.93 ]
Gonzalez 1999 11/93 22/92 12.6 % 0.44 [ 0.21, 0.93 ]
Hamann 1998 3/100 2/100 2.3 % 1.50 [ 0.26, 8.84 ]
Hull 2007 33/369 36/368 28.8 % 0.91 [ 0.55, 1.49 ]
Hull 2009 25/240 20/240 18.8 % 1.28 [ 0.69, 2.36 ]
Lopaciuk 1999 8/101 9/101 7.2 % 0.88 [ 0.33, 2.37 ]
Lopez 2001 2/81 7/77 3.9 % 0.29 [ 0.08, 1.12 ]
Pini 1994 16/93 8/94 9.7 % 2.17 [ 0.92, 5.09 ]
Romera 2009 6/119 13/122 8.1 % 0.46 [ 0.18, 1.18 ]
Veiga 2000 8/50 6/50 5.6 % 1.39 [ 0.45, 4.28 ]
Total (95% CI) 1296 1296 100.0 % 0.88 [ 0.67, 1.15 ]
Total events: 114 (LMWH), 128 (VKA)
Heterogeneity: Chi2 = 15.23, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 LMWH versus VKA for total period of 12 months of follow-up (category I and II
trials), Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 9 LMWH versus VKA for total period of 12 months of follow-up (category I and II trials)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 2/52 7.1 % 1.04 [ 0.14, 7.62 ]
Gonzalez 1999 1/93 2/92 5.5 % 0.50 [ 0.05, 4.91 ]
Hamann 1998 0/100 2/100 3.7 % 0.13 [ 0.01, 2.16 ]
Hull 2007 12/369 17/368 51.3 % 0.70 [ 0.33, 1.46 ]
Lopaciuk 1999 1/101 1/101 3.7 % 1.00 [ 0.06, 16.10 ]
Lopez 2001 0/81 4/77 7.2 % 0.12 [ 0.02, 0.89 ]
Pini 1994 3/93 3/94 10.7 % 1.01 [ 0.20, 5.12 ]
Romera 2009 1/119 3/122 7.3 % 0.37 [ 0.05, 2.68 ]
Veiga 2000 0/50 2/50 3.6 % 0.13 [ 0.01, 2.15 ]
Total (95% CI) 1056 1056 100.0 % 0.56 [ 0.33, 0.95 ]
Total events: 20 (LMWH), 36 (VKA)
Heterogeneity: Chi2 = 5.84, df = 8 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
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trials), Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 9 LMWH versus VKA for total period of 12 months of follow-up (category I and II trials)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 5/52 3.1 % 0.42 [ 0.09, 1.93 ]
Gonzalez 1999 5/93 3/92 3.6 % 1.66 [ 0.40, 6.83 ]
Hamann 1998 1/100 1/100 0.9 % 1.00 [ 0.06, 16.10 ]
Hull 2007 60/369 59/368 46.3 % 1.02 [ 0.69, 1.51 ]
Hull 2009 22/240 21/240 18.2 % 1.05 [ 0.56, 1.97 ]
Lopaciuk 1999 6/101 6/101 5.3 % 1.00 [ 0.31, 3.20 ]
Lopez 2001 9/81 6/77 6.3 % 1.47 [ 0.51, 4.24 ]
Pini 1994 11/93 8/94 8.0 % 1.44 [ 0.56, 3.70 ]
Romera 2009 2/119 2/122 1.8 % 1.03 [ 0.14, 7.37 ]
Veiga 2000 10/50 7/50 6.6 % 1.52 [ 0.54, 4.30 ]
Total (95% CI) 1296 1296 100.0 % 1.09 [ 0.84, 1.43 ]
Total events: 128 (LMWH), 118 (VKA)
Heterogeneity: Chi2 = 3.03, df = 9 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 LMWH versus VKA for total period of 12 months of follow-up (category I
trials), Outcome 1 Incidence of recurrent VTE.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 10 LMWH versus VKA for total period of 12 months of follow-up (category I trials)
Outcome: 1 Incidence of recurrent VTE
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 5/52 4.2 % 0.42 [ 0.09, 1.93 ]
Gonzalez 1999 11/93 22/92 17.2 % 0.44 [ 0.21, 0.93 ]
Hull 2007 33/369 36/368 39.5 % 0.91 [ 0.55, 1.49 ]
Hull 2009 25/240 20/240 25.8 % 1.28 [ 0.69, 2.36 ]
Pini 1994 16/93 8/94 13.3 % 2.17 [ 0.92, 5.09 ]
Total (95% CI) 845 846 100.0 % 0.95 [ 0.70, 1.30 ]
Total events: 87 (LMWH), 91 (VKA)
Heterogeneity: Chi2 = 9.63, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
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trials), Outcome 2 Incidence of major bleeding.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 10 LMWH versus VKA for total period of 12 months of follow-up (category I trials)
Outcome: 2 Incidence of major bleeding
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 4/52 13.8 % 0.52 [ 0.10, 2.67 ]
Gonzalez 1999 1/93 1/92 4.8 % 0.99 [ 0.06, 15.94 ]
Hull 2007 12/369 17/368 67.3 % 0.70 [ 0.33, 1.46 ]
Pini 1994 3/93 3/94 14.1 % 1.01 [ 0.20, 5.12 ]
Total (95% CI) 605 606 100.0 % 0.72 [ 0.39, 1.32 ]
Total events: 18 (LMWH), 25 (VKA)
Heterogeneity: Chi2 = 0.38, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 LMWH versus VKA for total period of 12 months of follow-up (category I
trials), Outcome 3 Mortality.
Review: Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Comparison: 10 LMWH versus VKA for total period of 12 months of follow-up (category I trials)
Outcome: 3 Mortality
Study or subgroup LMWH VKA
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daskalopoulos 2005 2/50 5/52 3.9 % 0.42 [ 0.09, 1.93 ]
Gonzalez 1999 5/93 3/92 4.5 % 1.66 [ 0.40, 6.83 ]
Hull 2007 60/369 59/368 58.6 % 1.02 [ 0.69, 1.51 ]
Hull 2009 22/240 21/240 23.0 % 1.05 [ 0.56, 1.97 ]
Pini 1994 11/93 8/94 10.1 % 1.44 [ 0.56, 3.70 ]
Total (95% CI) 845 846 100.0 % 1.05 [ 0.78, 1.42 ]
Total events: 100 (LMWH), 96 (VKA)
Heterogeneity: Chi2 = 2.24, df = 4 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1234
#2 MESH DESCRIPTOR Thromboembolism 896
#3 MESH DESCRIPTOR Venous Thromboembolism 239
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
2001
#5 (thromboprophyla* or thrombus* or thrombotic* or throm-
bolic* or thromboemboli* or thrombos* or embol*):TI,AB,
KY
17573
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(Continued)
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
734
#7 (PE or DVT or VTE):TI,AB,KY 4603
#8 (((vein* or ven*) near thromb*)):TI,AB,KY 6271
#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 20979
#10 MESH DESCRIPTOR Anticoagulants 3271
#11 MESH DESCRIPTOR Coumarins EXPLODE ALL TREES 1618
#12 (((vitamin k or vit k) near3 antagon*)):TI,AB,KY 370
#13 VKA:TI,AB,KY 140
#14 anticoagula*:TI,AB,KY 7493
#15 anti-coagula*:TI,AB,KY 146
#16 warfarin*:TI,AB,KY 2809
#17 *coum* :TI,AB,KY 834
#18 (Jantoven or Marevan or Lawarin or Waran or Warfant or
Dindevan):TI,AB,KY
4
#19 phenindione:TI,AB,KY 33
#20 (Sinthrome or Sintrom):TI,AB,KY 8
#21 (Marcumar or Falithrom):TI,AB,KY 10
#22 (aldocumar or tedicumar):TI,AB,KY 0
#23 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR
#17 OR #18 OR #19 OR #20 OR #21 OR #22
9306
#24 MESHDESCRIPTORHeparin, Low-Molecular-Weight EX-
PLODE ALL TREES
1488
#25 (low near4 hepar* ):TI,AB,KY 3132
#26 (LMWH or LMH):TI,AB,KY 802
#27 (nadroparin* or fraxiparin* or enoxaparin):TI,AB,KY 1620
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#28 (Clexane or klexane or lovenox):TI,AB,KY 42
#29 (dalteparin or Fragmin or ardeparin):TI,AB,KY 561
#30 (normiflo or tinzaparin or logiparin):TI,AB,KY 182
#31 (Innohep or certoparin or sandoparin or reviparin):TI,AB,KY 134
#32 (clivarin* or danaproid or danaparoid):TI,AB,KY 56
#33 (antixarin or ardeparin* or bemiparin*):TI,AB,KY 42
#34 (Zibor or cy 222 or embolex or monoembolex):TI,AB,KY 38
#35 (parnaparin* or rd 11885 or RD1185):TI,AB,KY 27
#36 (tedelparin or Kabi-2165 or Kabi 2165):TI,AB,KY 42
#37 (emt-966 or emt-967 or pk-10 169 or pk-10169 or pk10169)
:TI,AB,KY
8
#38 (fr-860 or cy-216 or cy216):TI,AB,KY 51
#39 (seleparin* or tedegliparin or seleparin* or tedegliparin*):TI,
AB,KY
1
#40 (“kb 101” or kb101 or lomoparan or orgaran):TI,AB,KY 31
#41 (parnaparin or fluxum or lohepa or lowhepa):TI,AB,KY 33
#42 (op 2123 or parvoparin):TI,AB,KY 1
#43 calciparin*:TI,AB,KY 22
#44 #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR
#31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR
#38 OR #39 OR #40 OR #41 OR #42
4570
#45 #9 AND #23 AND #44 1187
#46 15/02/2012 TO 31/10/2016:DL 308891
#47 #45 AND #46 446
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Appendix 2. Trials registries searches
ClinicalTrials.gov
44 studies found for: Thromboembolism OR thrombosis OR DVT in Condition AND
(vitamin k antagonist OR warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND heparin in Inter-
ventions
World Health Organization International Clinical Trials Registry Platform
496 records for 138 trials for: Thromboembolism OR thrombosis OR DVT in Condition AND
(warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND heparin in Intervention
ISRCTN Register
3 results found for (warfarin OR coumadin OR phenprocoumon OR acenocoumarol OR dicoumarol) AND (thromboembolism or
thrombosis or DVT)
Appendix 3. Glossary
anticoagulant: medicine that helps prevent blood clots
intravenous: into the vein(s)
oral anticoagulant: anticoagulant taken by mouth
parenteral anticoagulant: administration of anticoagulant by injection or infusion
subcutaneous: under the skin
F E E D B A C K
Anticoagulant feedback, 14 February 2011
Summary
Feedback received on this review and other reviews and protocols on anticoagulants is available on the Cochrane Editorial Unit website
at http://www.editorial-unit.cochrane.org/anticoagulants-feedback.
WH A T ’ S N E W
Last assessed as up-to-date: 11 November 2016.
Date Event Description
11 November 2016 New citation required but conclusions have not
changed
Reran searches, identified 1 new included study. Up-
dated review text and added ’Summary of findings’ ta-
ble. New author joined review team. No changes to
conclusions
11 November 2016 New search has been performed Reran searches. Identified 1 new included study.
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H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 4, 2000
Date Event Description
29 March 2012 New citation required but conclusions have not
changed
New review authors have taken over this review; up-
dated review and made no changes to conclusions
29 March 2012 New search has been performed New review authors have taken over this review: reran
searches, added 8 new included studies and long-term
follow-up data from 1 study. Assessed risk of bias for
all included studies
14 February 2011 Amended Added link to anticoagulant feedback
28 August 2008 Amended Converted to new review format
14 May 2003 New search has been performed Added 2 new studies to included studies and 3 to on-
going studies
C O N T R I B U T I O N S O F A U T H O R S
A Andras (AA) assessed trials for inclusion, extracted data, assessed risk of bias, analysed data, and drafted the manuscript.
A Sala Tenna (AST) drafted the manuscript.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We modified the original protocol as follows for the update published in 2012.
• We excluded trials that randomised only participants with cancer, as patients with malignancy are the topic of a different review
(Akl 2014).
• We added secondary outcomes that were the same as primary outcomes but were measured over a different time frame. Primary
outcomes now are measured during initial treatment covering three months, and secondary outcomes are considered for an additional
nine months, or longer if data are available.
• We changed assessment of the methodological quality of included trials to include the updated and recommended Cochrane
’Risk of bias’ tool (Higgins 2011).
For the 2017 update, we added a ’Summary of findings’ table, according to current Cochrane guidelines.
N O T E S
The ’Description of the condition’ section is based on a standard background section established by Cochrane Vascular.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticoagulants [adverse effects; ∗therapeutic use]; Hemorrhage [chemically induced; epidemiology]; Heparin, Low-Molecular-Weight
[adverse effects; ∗therapeutic use]; Incidence; Odds Ratio; Randomized Controlled Trials as Topic; Recurrence; Venous Thromboem-
bolism [∗drug therapy; mortality]; Venous Thrombosis [drug therapy]; Vitamin K [∗antagonists & inhibitors]
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MeSH check words
Humans
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